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Cellular senescence is a coordinated stress-response program that plays a 
central role in tumor suppression and aging associated degeneration. Senescent 
cells are characterized by the onset of various characteristics such as 
irreversible cell cycle arrest and increased β-galactosidase activity. Senescence 
can be triggered by various stresses such as DNA damage, oncogene 
activation, telomere attrition and oxidative stress. A major regulator of 
senescence is the tumor suppressor p53 which is triggered by various cellular 
stresses. p53 mediates senescence via modulation of its various downstream 
targets such as p21. The activation of p53 itself is tightly regulated by 
numerous pathways in order to prevent aberrant onset of p53 mediated 
senescence. Our laboratory has previously shown that the transcription factor 
Stra13 causes growth arrest and functions as a positive regulator of p53. In this 
work we have further investigated its role in cellular senescence.  Our data 
demonstrate that senescence mediated by Stra13 is p53 dependent. This is 
accompanied by increased p53 levels and its acetylation at lysine 379. Since 
Sirt1 is a NAD
+
-dependent histone deacetylase that catalyses the deacetylation 
of mouse p53 at lysine 379, we hypothesized that Stra13 and Sirt1 antagonizes 
each other to regulate p53 activity and senescence. Indeed, expression of Sirt1 
or increase in its activity counteracts Stra13 mediated p53 acetylation and 
senescence. Interaction studies reveal that under cellular stress, Sirt1 
dissociates from Stra13 and p53, while p53-Stra13 interaction is strengthened. 
Our findings provide new insights to the modulation of p53 mediated cellular 
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Senescence originates from the latin word senex which means old age or old 
man. It was first coined by Hayflick and Moorhead to describe their 
pioneering observation of human embryonic lung tissue derived diploid 
fibroblast exhausting their proliferative potential after a limited number of 
population doublings in vitro (Hayflick and Moorhead, 1961). This state of 
cellular arrest is irreversible even with introduction of mitogenic stimuli. The 
maximum number of doublings before a cell senesces is thus known as the 
Hayflick limit.  
Hayflick hypothesized that the avoidance from senescence by mammalian 
somatic cells would have required the acquisition of cancer cell qualities. In 
addition, Hayflick implied that cellular growth arrest observed during 
senescence might be a link to explain the mechanisms of aging in vivo 
(Hayflick, 1965). After almost fifty years, these statements still stand strong as 
findings affirm the central role of senescence as a safeguard mechanism in 
halting proliferation of cells which have accumulated neoplastic changes, and  
as an inhibitor of cellular renewal via the accumulation of senescent cells and 
the depletion of stem cell functions leading to aging (Collado et al., 2007). 
Since the time of Hayflick, various groups have identified major triggers and 
molecular pathways involved in the regulation of senescence and the list of 
regulatory elements to be added to the pathways have been ever growing, 
indicating the complexity of senescence regulation. It is therefore vital to 
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continue to unravel the mechanisms of senescence which sit at the cross roads 
of cancer and aging. 
1.1.1. Characteristics of cellular senescence 
Initially described as a process where normal cells fail to undergo further 
proliferation, numerous other hallmarks of senescence have been identified. 
However, not all senescent hallmarks may be detected in a single senescent 
cell as it varies with the factors such as species, cell types and senescence 
inducing cues. 
1.1.1.1. Cell morphology 
The most notable characteristic of a senescent cell is the drastic morphological 
changes it acquires which differ from its pre-senescent counterparts. A 
senescent cell typically displays an increase in cell size and adopts a flattened 
appearance in vitro. These changes in morphology are a result of the 
reorganization of the cytoskeletal structures such as the down-regulation of 
actin and tubulin expression, up-regulation of vimentin, increase in actin stress 
fibers and redistribution of focal adhesion proteins (Nishio et al., 2001; Nishio 
and Inoue, 2005; Chen et al., 2000).  
Cytoplasmic and nuclear changes are also detected in senescent cells in the 
form of lysosome accumulation and centrally localized nucleus that are 
enlarged and have altered intra-nuclear contents (Kurz et al., 2000; Mitsui and 





1.1.1.2. Growth arrest 
The inability to progress through the cell cycle is also a well depicted 
senescence characteristic. Unlike quiescent cells that are arrested in a phase 
known as G0, senescent cells which are typically arrested in the G1 phase are 
not able to proliferate despite exposure to mitotic stimuli such as fibroblast 
growth factor and tumor necrosis factor in spite of retaining functional growth 
factor receptors (di Leonardo et al., 1994; Herbig et al., 2004; Aggarwal et al., 
1995). 
The failure to undergo cell cycle progression in senescent cells lies in the 
expression and activation of p16INK4A, p14ARF (p19ARF in mouse), 
retinoblastoma and p53 that are important in the cell cycle arrest pathways 
(Alcorta et al., 1996; Dimiri et al., 2000; Shay et al., 1991). Genetic 
manipulation of some of these genes has shown to be able to reverse or 
prevent the onset of the senescent phenotype (Beauséjour et al., 2003; Zhang 
et al., 2012). However, the molecular mechanisms by which senescence is 
regulated differ in different species, cell and trigger types. This will be further 
elaborated in later sections. 
1.1.1.3. Apoptotic stimuli resistance 
Senescent cells have the capability of surviving in culture for extended periods 
despite being growth arrested. Most types of senescent cells are also refractory 
to apoptotic stimuli as compared to their normal or quiescent counterparts. For 
instance, senescent WI-38 fibroblasts are resistant to serum starvation induced 
apoptosis, whereas quiescent WI-38 fibroblasts are susceptible (Wang, 1995). 
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Thus apoptosis resistance may contribute to the prolonged lifespan of 
senescent cells in culture. 
The degree of resistance to apoptotic stimuli by senescent cells may differ in a 
cell type manner. For example, senescent endothelial cells are more 
susceptible than senescent fibroblast cells to ceramide induced apoptosis 
(Hampel et al., 2004). This could be a phenotypic reflection of the differential 
modulation of regulatory mechanisms which are common to both senescence 
and apoptosis, as findings indicate alterations of proteins in the apoptotic 
pathway such as caspase and p53 could switch a cell between senescent or 
apoptotic status (Rebbaa et al., 2003; Seluanov et al., 2001).  
1.1.1.4. β-galactosidase activity 
A commonly utilized senescence marker is the detection of β-galactosidase 
activity. β-galactosidase is a lysosome localized hydrolase that cleaves β-D-
galactosides to release β-D-galactose. Accumulation of lysosome in senescent 
cells correlates with increased β-galactosidase activity which is detectable at 
pH 6.0 (Kurz et al., 2000). Assays exploit this enzymatic reaction to stain the 
perinuclear regions blue in senescent cells.  
Despite being a widely utilized marker, β-galactosidase activity is not specific 
for senescence as it is detected in immortalized cancer cell lines (Krishna et al., 
1999). Treatment of cells with hydrogen peroxide or cells grown to confluency 
also increases β-galactosidase expression (Severino et al., 2000; Yang and Hu, 
2005). Nevertheless, β-galactosidase is still a useful marker for senescence.   
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1.1.1.5. Senescence associated heterochromatin foci (SAHF), Senescence 
associated DNA damage foci (SDF) and Senescence associated secretory 
phenotype (SASP) 
Senescence associated heterochromatin foci (SAHF) are regions of condensed 
chromatin that possess heterochromatin associated histone modifications and 
proteins such as trimethylation of histone 3 at lysine 9 and heterochromatin 
protein 1 (HP1) respectively (Narita et al., 2003). SAHF is detected via the 
preferential binding of deoxyribonucleic acid (DNA) binding dyes to these 
regions. Interestingly, SAHFs are found in regions which contain target genes 
of the E2F transcription factor involved in cell proliferation pathways (Narita 
et al., 2003). It is thought that SAHFs are formed to silence the transcription 
of E2F target genes and consequently result in senescence. 
Senescence associated DNA damage foci (SDF) are foci associated with the 
presence of DNA damage which is one of the triggers of cellular senescence 
(Mallette et al., 2007). These foci contain DNA damage response proteins 
such as H2AX, Ataxia telangiectasia mutated protein (pATM) and Csk 
homologous kinase 2 protein (pCHK2) (Di Micco et al., 2006; Bartkova et al., 
2005). SDF is believed to be a product of DNA damage response which is 
activated to initiate cellular senescence. However, SDF may not be present in 
all senescent cells as in the case of senescent K-RasV12-induced lung 
adenoma lesions (Efeyan et al., 2009); but its absence does not preclude 
senescence.       
In recent studies, senescent cells have been shown to express secretory 
proteins which include growth factors, cytokines that have paracine and/or 
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autocrine functions that are collectively termed as senescence associated 
secretory phenotype (SASP) (Ascosta et al., 2008; Kuilman et al., 2008).  
Some SASPs such as insulin-like growth factor binding protein 7 (IGFBP7) 
have tumor suppressive effects while others such as growth-related oncogene 
α (GROα) are associated with progression of malignancy (Wajapeyee et al., 
2008; Coppé et al., 2010). The seemingly varied and opposing effects of 
individual secretory factors in the SASP cocktail seem to contextually indicate 
senescence as either a tumor suppression or progression phenomenon 
depending on the profile of SASP expressed. 
1.1.2. Major senescence triggers 
The initial discovery of the cause of senescence began with the deciphering of 
why primary human diploid cells fail to proliferate for extended periods in 
culture as observed by Hayflick. Later studies revealed that senescence can be 
triggered by a myriad of stimuli which activate various pathways in cells that 
may differ depending on species and cell type context. 
1.1.2.1. Telomere attrition 
Eukaryotes, unlike prokaryotes, have linear chromosomes instead of circular 
chromosomes (Zakian, 1995). The chromosome ends comprise repeats of 5’-
TTAGGG-3’ which is followed by single stranded 3’ overhang of guanine (G) 
repeats. In order to prevent the recognition of the exposed ends on the linear 
chromosomes by the cell’s DNA repair mechanisms as DNA breaks, the 
chromosome ends are physically protected with a group of telomere binding 
proteins. These proteins associate with the 3’ overhang which folds into a loop 
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structure known as the T-loop, thus forming the shelterin complex (de Lange, 
2005). 
The length of telomeres are maintained by telomerase, an enzyme which has a 
telomerase reverse transcriptase function and an RNA component that serves 
as a template for adding telomeric repeats. Together with the 3’ overhang of 
chromosome ends which act as primers for telomerase enzymes, the telomere 
ends can be elongated (Collins and Mitchell, 2002). 
In cells that lack or possess little telomerase expression, the chromosomal ends 
encounter a phenomenon known as end-replication problem. DNA 
polymerases are not able to fully replicate the ends of linear DNA resulting in 
loss of 50 to 500 base pairs after every DNA synthesis phase of the cell cycle 
(Harley et al., 1990). The gradual attrition of telomeres is recognized as 
double stranded DNA breaks which trigger the DNA damage response (DDR) 
mechanism (elaborated in later sections), resulting in the onset of the 
senescence phenotype (d'Adda di Fagagna et al., 2003). Recent studies have 
also pointed out that the loss of the telomere associated proteins could have 
induced senescence in an end replication problem independent manner 
(Blackburn, 2000; Blackburn, 2001). 
1.1.2.2. Oncogenes 
Despite the presence of telomeres in cultured cells such as mouse embryonic 
fibroblasts (MEFs), senescence still occurs after repeated passages. The 
senescent phenotype is unlikely caused by telomere erosion as mouse cells 
have relatively long telomeres which are maintained by telomerase (Sherr and 
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DePinho, 2000).  It is hypothesized that telomere independent factors may 
result in the senescent phenotype in these cells. 
H-RAS, an oncogene, was identified as the first trigger of telomere attrition 
independent senescence (Serrano et al., 1997). The RAS family which consists 
of H-RAS, K-RAS, N-RAS and V-RAS is a group of small GTPase proteins 
that function as binary switches in pathways depending on the phosphorylation 
status of the guanosine nucleotide bound to them. They are important in 
driving proliferation pathways (Malumbres and Pellicer, 1998). 
The response to RAS prior to the onset of senescence is thought to be biphasic 
where RAS induces an initial and abnormally high growth rate in primary 
diploid cells which is detected as erroneous proliferation, in turn activating 
growth arresting mechanisms resulting in senescence of cells (Di Micco et al., 
2007). This is accomplished through RAS’ ability to increase intracellular 
reactive oxygen species levels, the number of DNA replication origins and 
stalled replication forks, which in turn activate DNA damage responses to 
trigger the onset of senescence (Lee et al., 1999; Di Micco et al., 2006; 
Fridman and Tainsky, 2008). 
It is now known that the downstream components of RAS signaling pathways 
and also other oncogenes such as Myc, BRAF and E2F1 are able to trigger 
senescence in primary diploid cells (Zhu et al., 1998; Grandori et al., 2003; 





1.1.2.3. Oxidative stress 
Intracellular reactive oxygen species (ROS) are produced naturally by the 
electron transport chain and other enzymatic reactions as a result of aerobic 
metabolism. At physiologically normal levels, ROS function as important 
messenger molecules in signaling pathways (D'Autréaux and Toledano, 2007; 
Forman et al., 2010). However, excessive accumulation of ROS results in 
oxidative stress.  
The first observation of oxidative stress effect on the induction of senescence 
was made in MEFs cultured in physiological levels of oxygen (2-3%) where a 
delay or escape of the onset of senescence was seen as compared to MEFs 
cultured in 20% oxygen content used in tissue culture conditions (Packer and 
Fuehr, 1977; Poulios et al., 2007; Saito et al., 1995). ROS was further 
implicated as a causative agent of senescence when sub-cytotoxic levels of 
exogenous hydrogen peroxide, a form of ROS, induced senescence in human 
diploid fibroblasts and ROS induced senescence was rescued with antioxidants 
(Chen et al., 1998; McFarland and Holliday, 1994; Atamna et al., 2000). In 
addition, ROS triggered senescence is also accompanied with accelerated 
telomere erosion which is a hallmark of replicative senescence (Martin-Ruiz et 
al., 2004).   
The effect of ROS is thought to act via inducing oxidative DNA damage 
which triggers DNA damage responses leading to senescence (von Zglinicki, 
2002; Bertram and Hass, 2008). Recent studies suggest ROS may function as 
messenger molecules to regulate pathways critical for senescence induction. 
For example, ROS regulates the DNA damage response pathway to result in a 
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positive feedback loop which enhances further ROS accumulation thus 
strengthening the DNA damage response (Passos et al., 2010). In addition, 
positive regulation of proteins such as Seladin-1, an oxidative stress sensor 
and DDB2, a repressor of cellular antioxidant mechanisms by ROS results in 
further accumulation of ROS and activation of growth arrest pathways 
resulting in the onset of senescence (Wu et al., 2004; Roy et al., 2010). 
1.1.2.4. DNA Damage 
As mentioned earlier, triggers of senescence such as telomere attrition, 
oncogene induction and oxidative stress are shown to cause a common 
phenotype: DNA damage which are represented as DNA lesions. Irradiation 
and chemotherapeutic compounds which damage DNA are also known to 
induce senescence (Wahl and Carr, 2001). DNA damage initiates the DNA 
damage response which involves the recruitment of DNA damage sensing 
proteins such as ATM and ATR to the damage site and triggering of signaling 
cascades, leading to activation of cell arrest and repair pathways (d'Adda di 
Fagagna, 2008). 
The inactivation of proteins involved in DNA repair mechanisms which results 
in the accumulation and persistence of DNA damage in mice and cells can 
trigger the onset of senescence, reinforcing the relevance of DNA damage as a 
trigger of senescence (Frank et al., 2000; Ongusaha et al., 2003). The 
reversion of DNA damaged induced senescence can be achieved by the 
inactivation of important tumor suppressor proteins such as p16INK4A, 
retinoblastoma, p19ARF and p53 that are also involved in the molecular 
pathways of senescence (d'Adda di Fagagna, 2008). 
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1.1.3. Major protein regulators of senescence 
Cellular senescence is initiated and maintained by two major pathways: the 
p16INK4A- Retinoblastoma pathway and the p19ARF-p53 pathway. Both 
pathways have been widely studied via inactivation or depletion of the 
proteins in the pathways in relation to senescence. The p53 protein will be 
further elaborated in later sections. 
1.1.3.1. p16INK4A and Retinoblastoma 
p16INK4A is a cyclin dependent kinase inhibitor (CDKI) which retards the 
function of cyclin dependent kinases (CDKs) 4 to 6 that are vital for 
progression of the cell cycle through the G1 phase and phosphorylation of 
retinoblastoma, a tumor suppressor protein. The inhibition of these CDKs by 
p16INK4A allows retinoblastoma to remain in a hypophosphorylated status. 
Unphosphorylated retinoblastoma binds to the transcription factor E2F and 
inhibits E2F target genes encoding for cyclins E and A which are essential for 
cell cycle progression (Kaelin, 1999). 
The functions of p16INK4A and retinoblastoma have been intensively studied 
in the induction of senescence. Senescence inducing stress and progressive 
cell proliferation of primary cells are able to increase p16INK4A expression, 
while the dampening of p16INK4A via inactivation or removal positively 
correlates with immortalization of cells (Alcorta et al., 1996; Palmero et al., 
1997; Munro et al., 1999). Similarly, retinoblastoma remains 
hypophosphorylated in senescent human diploid fibroblasts even when 
subjected to growth stimuli (Dulić et al., 1993). Inactivation of retinoblastoma 
via viral proteins such as SV40 large T-antigen and herpes virus E7 protein 
12 
 
through their association with retinoblastoma’s E2F binding domain also 
facilitates cells in escaping senescence by allowing the release of E2F to 
induce transcription of cell cycle genes (Burkhart and Sage, 2008). 
1.2. p53, the guardian of the genome 
p53 was discovered as a protein associated with the SV40 large T-antigen 
oncoprotein in SV40 transformed cells, and later as a binding partner for 
adenoviral and papillomaviruses oncoproteins (Lane and Crawford, 1979; 
Linzer and Levine, 1979; Sarnow et al., 1982; Werness et al., 1990; Scheffner 
et al., 1990). It was then speculated that p53 is involved in the regulation of 
viral replication and viral induced tumorigenesis. The cloning of mutant p53 
cDNA initially classified it as an oncogene where it was found to promote 
transformation of cells (Eliyahu et al., 1984; Eliyahu et al., 1985; Parada et al., 
1984). However, the wildtype p53 cDNA inhibited transformation of cells by 
oncogenes (Finlay et al., 1989). 
Extensive observations of p53 levels and their respective phenotypes over the 
decade further cement p53 as a tumor suppressor. Li-Fraumeni syndrome 
patients who possess mutant p53 allele develop cancers with 100% penetrance 
(Malkin et al., 1990). Similar phenotypes are observed in p53 knockout mice 
where they develop tumors early in their lifespan (Donehower et al., 1992; 
Lozano, 2010). In addition, up to 50% of human cancers have p53 mutations 
on both alleles while some tumors have high levels of mutant p53 expression 
(Oliver et al., 2010; Robles and Harris, 2010; Bártek et al., 1991). These 




1.2.1. p53 Domains 
p53 protein generally functions as a transcription factor and consists of 4 
major types of domains: transactivation domain, DNA binding domain, 
tetramerization domain and the lysine rich C terminal domain. The 
transactivation domains lie in the N terminal region of p53 protein and span 
the amino acid residues of 1-40 and 40-60 (Figure 1.1). These domains recruit 
general transcription machinery, histone modifying enzymes such as p300 and 
co-activators during the transcription of p53 target genes (Gamper and Roeder, 
2008; Joerger and Fersht, 2007). 
p53 binds to the p53 response elements on its target genes via its DNA binding 
domain which spans amino acid residues 100-300 (Figure 1.1). Analysis of 
most cancer associated mutant p53 attributes the mutations to the DNA 
binding domain, indicating its importance in regulating p53 functions. The 
frequently mutated amino acid residues of the DNA binding domain include: 
arginine residues (R175, R248, R249, R273, R282) and glycine 245 (G245) 
(Brosh and Rotter, 2009). These mutations either disrupt DNA binding 
capability of p53 to its target genes and/ or contribute to the oncogenic 
potential of mutant p53 which is previously characterized prior to the isolation 
of wildtype p53 cDNA (Lang et al., 2004; Muller et al., 2009; Olive et al., 
2004). 
The C terminal region of p53 contains the tetramerization domain spanning 
amino acid residues 325-356 where four p53 subunits form a functional 
tetramer transcriptional unit (Figure 1.1). Finally, the basic lysine rich tail of 
p53 occupies amino acid residues 363-393 (Figure 1.1). This domain is 
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subjected to high amounts of post-translational modification of the lysine 
residues via acetylation, ubiquitination and methylation. These modifications 
play crucial roles in regulating p53 stability, activity and specificity (Kruse 
and Gu, 2009; Laptenko and Prives, 2006; Liu and Kulesz-Martin, 2006; 
Murray- Zmijewski et al., 2008). The regulation of p53 post-translational 




Figure 1.1. Schematic diagram of the domains of p53. p53 has a 
transactivation domain at the N terminus, a DNA binding domain, a 
tetramerization domain and a regulatory domain at the C terminus. 
 
1.2.2. p53 functions 
With over 50,000 publications, p53 is arguably one of the most studied 
proteins. Decades of research have revealed a myriad of p53 functions. p53 
has been shown to respond to a wide multitude of cellular stresses ranging 
from genotoxic stress, telomere erosion, hypoxia, heat or cold shock, 
oncogene activation, nutrient starvation to protein folding defects.  
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Depending on the environmental milieu, type and dose of stress, and cell type, 
p53 mediates a variety of cellular phenotypes ranging from growth arrest to 
apoptosis. Prolonged or severe stress usually triggers p53- mediated apoptosis. 
Activated p53 transcribes the components of the intrinsic and extrinsic 
apoptotic pathways such as BAX, BAK, PUMA, NOXA and FAS to induce 
cellular death (Riley et al., 2008; Zilfou and Lowe, 2009). Besides functioning 
as a transcription factor, p53 also induces mitochondrial outer membrane 
permeabilization (MOMP) to facilitate apoptosis. p53 is also reported to 
induce cellular senescence in some cell types (Kortlever et al., 2006; Riley et 
al., 2008). The role of p53 in senescence will be elaborated in later sections. 
Under mild stress perturbations, p53 induces cell cycle arrest via transcribing 
target genes which includes cell cycle inhibitors such as p21, GADD45A (El-
Deiry et al., 1992). Simultaneously, p53 target genes involved in DNA repair 
such as DDB2 and XPC are also transcribed to correct any genomic damage 
before the halt on cell cycle is released. This constant surveillance of p53 on 
the integrity of the genome to prevent any aberrations thus granted p53 the 
title of “guardian of the genome”. 
Besides regulating the apoptotic and cell cycle pathways, p53’s roles in other 
physiological processes such as metabolic regulation and embryogenesis have 
also been uncovered. Tumors have higher metabolic rates as demonstrated by 
altered metabolic pathways such as glycolysis. It is hypothesized that the 
change in the metabolic environment is causative of cellular transformation 
and this is termed as the “Warburg effect”. Recently, p53 is shown to induce 
the expression of TP53- inducible glycolysis and apoptosis regulator (TIGAR) 
protein to prevent the Warburg effect in cells (Vousdon and Ryan, 2009).  
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In the field of embryogenesis, p53 functions as a transcriptional activator for 
its target gene Leukemia inhibitory factor (LIF) which encodes for a cytokine 
that is vital for the implantation of the embryo in the uterus. p53 knockout 
mice display lower LIF levels and have defective embryo implantation (Hu et 
al., 2007). Other than the above examples, more of p53 functions in non-
apoptotic or non-cell arrest processes are currently being investigated. 
1.2.2.1. p53 and Senescence 
A central regulator of senescence is the tumor suppressor protein p53. p53 has 
been implicated in mediating senescence caused by triggers such as DNA 
damage, oxidative stress and oncogene expression (Di Leonardo et al., 1994; 
Parrinello et al., 2003; Serrano et al., 1997). The importance of p53 in 
senescence is seen in the inability of MEFs derived from p53 null mice to 
senesce (Harvey et al., 1993).  The above observations can be recapitulated in 
vitro via inactivation of p53 by various means such as nuclear injection of 
anti-p53 antibodies or lentivirus mediated RNAi knockdown of p53 in 
senescent cells to reinitiate proliferation and rescue the senescent phenotype. 
(Gire and Wynford-Thomas, 1998; Dirac and Bernards, 2003).  
The overexpression of viral oncoproteins SV40 large T-antigen and human 
papillomavirus E6 proteins also play a role in establishing p53 as a regulator 
of senescence. Binding of p53 to SV40 large T-antigen or E6 protein prevents 
its binding to target gene promoters, resulting in the inhibition of cell cycle 
arrest which leads to an extension in lifespan of the cells (Shay et al., 1991; 
Beauséjour et al., 2003;; Voorhoeve and Agami, 2003). 
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The importance of p53 in senescence can also be seen in the inability of  
senescent cells to resume proliferation with the overexpression of human 
telomerase reverse transcriptase (hTERT) which rescues telomere attrition 
mediated senescence without inactivating wildtype p53 (Beauséjour et al., 
2003). In addition, transgenic mice carrying constitutively active p53 alleles 
age prematurely (Tyner et al., 2002). These above findings exert p53’s 
importance in mediating senescence in both the cellular and organismal 
environment. 
The effect of p53 on senescence is primarily mediated through its 
transcriptional target proteins such as p21, a cyclin-dependent kinase inhibitor. 
p21 expression is enhanced in senescent cells and has been identified as a 
senescence inducing gene (El- Deiry et al 2003; Noda et al., 1994). Disruption 
of p21 allows MEFs and human fibroblast to escape senescence (Brown et al., 
1997; Harvey et al., 1993; Pantojo and Serrano, 1999).  
The mechanism by p21 induces senescence is through the halting of the 
progression of cell cycle via inhibiting cyclin E/CDK2  to result in a G1 phase 
arrest (Yang et al., 1995). Inhibition of cyclin E/CDK2 also results in the 
hypophosphorylation and activation of retinoblastoma protein which initiates 
cell arrest via inhibition of the transcription factor E2F (Harper et al., 1993). 
1.2.3. p53 regulation in senescence 
Since p53 functions as a master regulator for a variety of critical biological 
processes of the cell, it is tightly governed by an array of regulating 
mechanisms to ensure its proper function. 
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1.2.3.1. MDM2 regulation of p53 
MDM2 is an E3 ubiquitin ligase that acts as a negative regulator of p53 by 
keeping p53 at steady state basal levels (Mommard et al., 1992). The 
importance of MDM2 regulation is demonstrated in MDM2 null mice where 
embryonic lethality can be averted via restoration of p53 control by inhibition 
of p53 activity (Jones et al., 1995; Montes de Oca Luna et al., 1995). MDM2 
physically associates with p53, blocks p53 transactivation activity and poly-
ubiquitinates p53 on its C terminus. Ubiquitinated p53 is then exported out of 
the nucleus and targeted for proteosomal degradation (Lin et al., 1994; 
Kubbutat et al., 1997). MDM2 gene itself is a p53 transcriptional target, thus 
setting up a negative feedback MDM2-p53 autoregulatory loop (Wu et al., 
1993; Lahav et al., 2004). 
Upon stimulation by stress signals, the association of MDM2 and p53 is 
challenged by the tumor suppressor p19ARF. MDM2 is sequestered away 
from p53 by p19ARF, thereby stabilizing and activating p53 (Sherr, 1998).  
Recently, MDMX, a member of the MDM2 family, has also been found to 
inhibit p53 activity via its transactivation domain. Even though lacking E3 
ligase activity, MDMX can interact with and stabilized MDM2, leading to 
enhanced p53 degradation (Marine et al., 2007; Wade et al., 2010). 
1.2.3.2. p53 regulation by post-translational modification 
Besides the classical regulatory pathway of MDM2, p53 stability and activity 
is placed under additional control by a wide array of covalent post-
translational modifications of its amino acid residues. To date, more than 50 
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individual amino residues of p53 are shown to be modified in either in vivo or 
in vitro studies. These residues are subjected to post-translational 
modifications such as phosphorylation, acetylation, methylation, 
ubiquitination, glycosylation, neddylation, sumolyation and ribosylation 
(Meek, 1999; Appella and Anderson, 2001; Bode and Dong, 2004; Toledo and 
Wahl, 2006; Olsson et al., 2007; Anderson and Appella, 2009). These post-
translational modifications provide a complex network of p53 regulation, thus 
allowing p53 to illicit various specific responses to a multitude of cellular 
stresses. Among the variety of post-translational modifications, acetylation is 
well studied. 
1.2.3.2.1. Acetylation status of p53 
p53 is the first non-histone protein reported to be acetylated by histone 
acetyltransferases and is functionally regulated by acetylation (Gu and Roeder, 
1997). Acetylation involves the reversible covalent addition of acetyl group to 
the ε- amino group of lysine residues (MacDonald and Howe, 2009). Known 
acetylated lysine sites are located on amino acid residues 120, 164, 292, 305, 
320, 351, 357, 370, 372, 373, 381,382 and 386 of the human p53 protein (Gu 
and Roeder, 1997; Sakaguchi et al., 1998; Liu et al., 1999; Wang et al., 2003). 
Majority of these lysine residues lies in the C terminal domain.  
p53 acetylation is elevated during cellular stress and positively correlates with 
the increased activity and stability of p53 (Luo et al., 2000; Rodriguez et al., 
2000; Barley et al., 2001; Ito et al., 2001; Knights et al., 2006; Li et al., 2007; 
Kim et al., 2008; Zhao et al., 2008). Sequence specific DNA binding 
capability of p53 is reported to be heightened in the presence of acetylation 
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(Gu and Roeder, 1997; Sakaguchi et al., 1998; Liu et al., 1999; Luo et al., 
2004; Zhao et al., 2006). Enhanced DNA binding capacity of acetylated p53 is 
also attributed to the p53 conformational change via the neutralization of 
positive charges on the C terminal tail by acetylation (Gu and Roeder, 1997; 
Mc Kinney K et al., 2004; Anderson et al., 1997). The acetylated sites also act 
as docking regions for the recruitment of histone acetyl transferases such as 
CBP/p300 and co-transcriptional factors to facilitate p53 transcriptional 
activities (Goodman and Smolik, 2000). These studies highlight the 
importance of p53 acetylation in regulating its activity. 
p53 acetylation does not just function as a standalone post-translational 
modification, but is integrated into the complex post-translational modification 
network of p53 regulation where inter-dependencies of different types of post-
translational modification exist in this network. Phosphorylation of p53 is 
shown to sequentially promote or inhibit p53 acetylation status. 
Phosphorylation of S378 and T377 reduces acetylation of K373, K382 and 
K320 while phosphorylation of S366 and 387 enhance acetylation of these 
sites (Ou et al., 2005; Sakaguchi et al., 1998).  
Competitive regulation between acetylation and other types of post-
translational modifications such as ubiquitination in p53 is also present. The 
ubiquitination sites on the C terminus of p53 coincide with the six sites of 
acetylation. Ubiquitination and acetylation are mutually exclusive where 
acetylation of the C terminus in vitro prevents its ubiquitination by MDM2 
and thus stabilizes p53 (Rodriguez et al., 2000; Sakaguchi et al., 1998; Ito et 
al., 2001; Li et al., 2002). However, methylation of C terminus sites such as 
K382 inhibits the acetylation of these sites and indirectly promotes their 
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ubiquitination, leading to the destabilization of p53 protein. On the other hand, 
methylation of p53’s K370 and K372 seem to promote the acetylation of p53 
at the same sites which enhances p53 activity (Huang et al., 2006; Ivanov et 
al., 2007; Kurash et al., 2008; Shi et al., 2007). 
Despite the vast in vitro evidences of p53 regulation by acetylation of its C 
terminus, in vivo data from 6KR and 7-KR knock in mice models suggest 
otherwise. These mice have lysine sites on p53 C terminus substituted with 
arginine. Wildtype and knock in mice display similar p53 levels in embryonic 
fibroblast and thymocytes, suggesting that the C terminus of p53 is 
preferentially ubiquiunated by MDM2 but is not essential for p53 degradation 
(Feng et al., 2005; Krummel et al., 2005). However, these knock in mice have 
impaired p53-mediated transcription of certain target genes such as p21, 
indicating the relevance of p53 acetylation in regulating its transcriptional 
activity (Feng et al., 2005).  
1.3. Stra13, a bHLH-Orange transcription factor 
Stra13 belongs to a family of transcription factors known as the basic helix-
loop-helix orange (bHLH-Orange) factors which play important roles in 
regulating biological functions ranging from myogenesis and neurogenesis to 
apoptosis (Sun et al., 2007; Ishibashi et al., 1995; Hirata et al., 2001; 
Hatakeyama et al., 2004; Thin et al., 2007). This group is a sub-family of the 
helix-loop-helix super family, which contains seven classes based on their 
tissue distribution, dimerization capabilities and DNA binding specificities 
(Murre at al., 1994). The bHLH-Orange transcription factors are differentiated 
from other helix-loop-helix factors by the presence of a proline residue in their 
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basic motifs, and an additional orange domain which provides additional 
protein-protein interaction regions (Dawson et al., 1995). 
Stra13 is further classified under the Stra13/Dec sub-family under the bHLH-
orange family (Figure 1.2). Independently cloned from the BHLHB2 gene by 
four groups from three different mammalian organisms, it has been given 
numerous names: Differentially Expressed in Chondrocytes 1 (DEC1), E47 
interacting protein 1 (Eip1), and Cytokine response gene 8 (CR8) in human; 
Enhancer-of-Split and Hairy-related protein-2 (Sharp-2) in rat; Stimulated by 
retinoic acid 13 (Stra13) or Clast5 in mouse (Boudjelal et al., 1997; Seimiya et 
al., 2002; Shen et al., 1997; Dear et al., 1997; Beadling et al., 2001; Rossner 
et al., 1997). 
1.3.1. Stra13 domains 
Stra13 is a 411 kilo dalton protein that contains a bHLH motif, an orange 
domain and a proline rich domain (Figure 1.2). Similar to all bHLH-Orange 
transcription factors, Stra13 has a bHLH motif situated at the N terminal 
region of the protein. However, the proline amino acid residing in the basic 
region of the bHLH motif which defines the bHLH-Orange group of 
transcription factors is situated two residues closer to the N terminus 
compared to Hes proteins, the founding members of the bHLH-Orange 
subfamily (Boudjelal et al., 1997), suggesting variance in DNA binding 
affinities. 
The bHLH motif of Stra13 consists of 2 portions: the basic region and the 
helix-loop-helix region. The basic region consists of mostly basic amino acids 
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such as arginine and lysine which are directly involved in protein-DNA 
interaction.  
The helix-loop-helix region consists of two α helices separated by a flexible 
loop, which allows Stra13 to homodimerize or heterodimerize with other 
bHLH proteins. Stra13 binds as dimers to transcriptional regulatory regions of 
its target genes containing cis acting elements of hexanucleotide sequences of 
5’-CANNTG-3’ known as E box sequences (N represents any amino acids). 
Stra13 binds to sequence 5’-CACGTG-3’ with high affinity and 5’-CATGTG-
3’, 5’-CACGTN-3’, 5’-CACGCG-3’ with lower affinities (St-Pierre et al., 
2002; Zawel et al., 2002). 
The orange domain of Stra13 is located at its central region of the protein 
sequence. Approximately 35 kilo daltons, it is also a defining characteristic of 
all bHLH-Orange transcriptional factors. As mentioned earlier, the orange 
domain has been suggested to mediate additional protein-protein interactions 
of Stra13 and other proteins (Dawson et al., 1995). 
The C terminus of Stra13 contains a proline rich region which is a 
characteristic of all members of the bHLH-orange domain but little is known 
about its function. Unlike the other Hes and Hey sub-family of bHLH-Orange 
transcription factors, Stra13 lacks the tetra-peptide motif of tryptophan-
arginine-proline-tryptophan (WRPW motif) or tyrosine-arginine-proline-
tryptophan (YRPW motif) which flanks the proline rich region at the C 
terminus of Hes and Hey proteins respectively. The WRPW motif of Hes 
protein is crucial for the recruitment of corepressor transducin-like enhancer of 
split (TLE) to facilitate its transcriptional repression of genes (Fisher et al., 
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1996; Grbavec and Stifani, 1996). Stra13 which lacks WRPW motif does not 
recruit TLE, but interacts with co-repressors such as HDAC1, NCoR and 
mSin3A at its C terminus to mediate gene repression (Sun, 2000). In addition, 
deletion of the C terminus of Stra13 decreases its transcriptional activity, 
indicating that both the bHLH and C terminal regions of Stra13 are essential 
for its transcriptional activity (Boudjelal et al., 1997; St-Pierre et al., 2002; 
Sato et al., 2004; Yun et al., 2002; Li et al., 2004). 
 
Figure 1.2. Schematic diagram of the classification of mammalian bHLH-
O transcriptional factors. Stra13 is classified under Stra13/Dec sub-family. 
Stra13 contains bHLH motif, orange motif and a proline rich C terminus. It 
lacks the WRPW and YRPW motifs. (Adapted from Translational 
oncogenomics. 2007, 2: 105-118) 
 
1.3.2. Stra13 functions 
Stra13 regulates a wide variety of processes of many physiological systems 
such as neuronal differentiation, adipogenesis, muscle regeneration, T cell 
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regulation and circadian rhythm. In particular, Stra13 functions in relation to 
growth arrest, apoptosis and senescence will be elaborated in later sections.  
Stra13 affects differentiation and/or regeneration of a number of cell types. 
For instance, overexpression of Stra13 promotes the neuronal differentiation 
of P19 embryonal carcinoma cells instead of mesodermal/endodermal 
differentiation (Boudjelal et al., 1997). 
During skeletal muscle regeneration, the Notch protein positively regulates 
activation of muscle satellite cells and precursor cell proliferation. This 
process also inhibits the differentiation of myoblast to form muscle fibers. 
Stra13 inhibits notch activity to promote myoblast differentiation (Sun et al., 
2007). In addition, Stra13 protects muscle cells from oxidative stress mediated 
necrosis as evident by increased degeneration of injured muscles in Stra13 null 
mice (Vercherat et al., 2009). 
The process of adipogenesis is inhibited by hypoxia. The hypoxia-inducible 
transcription factor 1 alpha (HIF1α) inhibits PPAR gamma 2 protein which is 
a mediator of adipogenic differentiation. Stra13, a target gene of HIF1α 
functions as an effector of HIF1α to inhibit adipogenesis during hypoxia. 
Deficiency in Stra13 allows cells to be resistant to adipogenic inhibitory cues 
during hypoxia (Yun et al., 2002). 
Stra13 plays a role in the regulation of lymphocytes homeostasis as Stra13 null 
mice show accumulation of spontaneously activated T cells and develop 
autoimmune disease (Sun et al., 2001). 
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Stra13 is also involved in the mediation of circadian rhythmically regulated 
genes. CLOCK-BMAL1, a member of the CLOCK gene family activates 
Stra13 in a rhythmic manner in mouse peripheral organs. Stra13 -/- mice show 
altered expression of 42 target genes which are regulated by CLOCK proteins, 
indicating that Stra13 mediates CLOCK regulation of these genes (Grechez-
Cassiau et al., 2004). 
1.3.2.1. Stra13 in cancer, apoptosis, cell cycle arrest and senescence 
Besides the above mentioned functions, Dec1, the human version of Stra13 is 
also widely studied in the field of carcinogenesis. Analysis of endogenous 
Dec1 expression in tumors derived from human cancers such as gastric cancer, 
hepatocellular carcinoma and breast cancer reveals the overexpression of 
endogenous Dec1 compared to their non-neoplastic counterparts (Jia et al., 
2013; Shi et al., 2011; Chakrabarti et al., 2004). Dec1 therefore is suggested as 
a marker for these cancers. Elevated Dec1 expression correlates with increased 
invasiveness of breast cancer and decreased differentiation of gastric cancer, 
indicating its role in promoting tumor progression (Jia et al., 2013; 
Chakrabarti et al., 2004). In contrast to gastric cancer, Dec1 level seems to 
positively correlate with the differentiation status of hepatocellular carcinoma, 
suggesting varying roles Dec1 plays in different cancers (Jia et al., 2013; Shi 
et al., 2011). 
Despite a number of correlative studies that have been published on Stra13 in 
cancers, the mechanisms of how Stra13 regulates cancer progression is poorly 
understood. A few studies indicate Stra13 is a regulator of apoptosis and/ or 
cell cycle arrest in neoplastic and non-neoplastic cells. Upon pacitaxel 
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treatment, Dec1 knock down in MCF-7 by siRNA decreases cleaved poly 
(ADP-ribose) polymerase (PARP), an indication of decreased apoptotic 
activity (Wu et al., 2011). Stra13 null thymocytes have impaired apoptosis 
upon irradiation (Thin et al., 2007). Both studies suggest Stra13 as having pro-
apoptotic function.  
On the contrary, Stra13 has also been depicted as an anti-apoptotic protein. 
Dec1 is down-regulated in HepG2 cells after treatment with 8-
methoxypsoralen (8-MOP), an apoptotic inducing compound. Overexpression 
of Dec1 antagonizes 8-MOP induced apoptosis. Stra13 is also a mediator of 
transforming growth factor-β (TGF-β) signaling which promotes the survival 
of mouse mammary carcinoma cell line JygMC(A) and Dec1 overexpression 
prevents apoptosis induced by TGF-β inhibitors( Peng et al., 2012). 
Stra13 is reported to be also involved in inducing cell arrest. Cyclin D1, an 
essential component for the G1/S transition of the cell cycle, contains a DEC-
response element in its promoter. Stra13 binds to the DEC-response element 
and represses transcription of Cyclin D1 (Bhawal et al., 2011; Wang et al., 
2012), thus arresting the cell cycle. Inactivation of Stra13 relieves Cyclin D1 
repression and promotes proliferation.  
1.3.2.1.1. Stra13 in relation with p53 and senescence 
As apoptosis and cell cycle are regulated by p53, and Stra13 is also reported to 
regulate both processes, questions arose as to whether Stra13 may play a role 
in these processes mediated by p53. In 2007, in vitro overexpression of Stra13 
was reported to regulate p53 levels. Further investigations revealed that Stra13 
and p53 physically associate with each other via the bHLH domain in Stra13 
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and the C terminus in p53. This interaction shields the C terminus of p53 from 
Mdm2 mediated ubiquitination, preventing its nuclear export and degradation. 
This suggests Stra13 enhances the stability of p53 (Thin et al., 2007). 
Other groups have reported Stra13 as a target gene of p53 transcription 
activity. Upon cellular stress, p53 binds to p53 response elements on the 
Stra13 promoter to facilitate its transcription. Stra13 then mediates p53 
dependent senescence in response to cellular stress, providing first evidence of 
Stra13 involvement in senescence (Qian et al., 2008).  
Similar findings on the role of Stra13 in senescence were also reported later 
where endogenous Stra13 expression was found to positively correlates with 
senescence of squamous cell carcinomas, and the tyrosine kinase inhibitor 
sunitinib mediated senescence of renal carcinoma cells which is accompanied 
by elevated p53 and Stra13 levels (Xu et al., 2012; Zhu et al., 2013). 
Recently, Stra13 was reported as a determinant of p53 dependent cell fate 
decision. Qian et al., 2012 have found that Stra13 overexpression does not 
alter p53 protein levels even upon induction of DNA damage with 
camptothecin, contradicting the findings of Thin et al., 2007 which indicated 
of Stra13 increases p53 protein levels.  
It was also demonstrated that macrophage inhibitory cytokine 1 (MIC-1), a 
p53 target gene, contains response elements for both p53 and Stra13 on its 
promoter. Stra13 binds to MIC-1 promoter and displaces p53 from its response 
element due to the close proximity of the two response elements, repressing 
p53 mediated MIC-1 transcription and apoptosis. Stra13 does not inhibit the 
ability of p53 to transcribe its other target genes such as p21 or Mdm2 as the 
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response elements for Stra13 and p53 on promoters of p21 and Mdm2 are not 
in close proximity. It is hypothesized that Stra13 forms a feedback loop to 
facilitate stress induced cell survival via inhibition of pro-apoptotic MIC-1 
(Qian et al., 2012). 




Silent information regulator 1 (Sirt1) also known as Sirtuin 1 belongs to the 
family of histone deacetylases (HDACs) whose primary function is to 
deacetylate lysine residues on histones and /or proteins. Unlike other HDACs, 
Sirt1 requires the presence of the essential cofactor nicotinamide adenine 
dinucleotide (NAD
+
) for its catalytic activity (Chang et al., 2002). Sirt1 
cleaves the nicotinamide ribosyl bond of NAD
+
 and transfers the acetyl group 
from the acetylated protein substrate to the co-factor, generating the 
deacetylated form of the protein, nicotinamide and 2’ and 3’-O-acetyl-ADP-
ribose (Borra et al., 2002; Liou et al., 2005; Lee et al., 2008).  Sirt1 and other 
NAD
+ 
dependent deacetylases are categorized as Class III HDACS and are 
collectively known as sirtuins.  
The mammalian sirtuin family contains seven members which are defined by 
their homology to the founding orthologue Sir2 from Saccharomyces 
cerevisiae. All members of the Sirtuin family are characterized by the 
presence of a conserved 275 residue long catalytic domain (Brittain and Ottow, 
2007). Sirt1 is further classified as a class 1a sirtuin based on phylogenetic 




1.4.1. Sirt1 functions 
Sirt1 is the most extensively studied member of the sirtuin family. It is 
primarily a nuclear protein but does have cytoplasmic-nucleus shuttling 
functions. Sirt1 is usually associated with euchromatin where it facilitates 
heterochromatin formation via deacetylation of lysine residues at position 9 
and 26 of histone 1, 14 of histone 3 and 16 of histone 4 to mediate gene 
repression (Vaquero et al., 2004; Imai et al., 2000). Besides deacetylating of 
histones, Sirt1 also mediates deacetylation of non-histone protein targets such 
as p53, FOXO1 and PGC1α to regulate various physiological processes. 
Sirt1 regulates a wide variety of major biological processes ranging from 
metabolism, cardiovascular health, neuronal function and carcinogenesis. Sirt1 
functions as a metabolic sensor of the cell by regulating important pathways 
such as glyconeogenesis, glycolysis, fatty acid oxidation and insulin signaling 
(Luo et al., 2001). Deacetylation of Sirt1 target genes such as PGC1α, STAT3, 
TORC2 and FOXO1 in the liver stimulate glyconeogenic gene expression 
while inhibiting the glycolysis pathway (Rodgers et al., 2005; Fescas et al., 
2005; Liu et al., 2008; Nie et al., 2009). PGC1α deacetylation by Sirt1 also 
promotes its interaction with PPARα and enhances its transcription target 
genes involved in fatty acid oxidation pathway (Purushotham et al., 2009). 
Sirt1 also plays an important role in maintaining insulin sensitivity by 
silencing the transcription of protein tyrosine phosphotase 1B (PTP1B) which 
dephosphorylates insulin receptors to negatively regulate insulin signaling 
(Sun et al., 2007). 
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Besides maintaining the metabolic homeostasis of the organism, Sirt1 also 
demonstrates the ability to protect various organ systems from age related 
deterioration.  Sirt1 appears to have cardiovascular protective functions. It is 
highly expressed in endothelial cells and deacetylates endothelial nitric oxide 
synthase resulting in inhibition of senescence in these cells (Nisoli et al., 2005; 
Ota et al., 2008). Sirt1 inhibits the expression of cardiac smooth muscle 
angiotensin receptor (AT1) which decreases reactive oxygen species in these 
cells (Li et al., 2011; Miyazaki et al., 2008; Benigni et al., 2009). The above 
cumulative effects of Sirt1 are thought to mitigate atherosclerosis.  
In neurodegenerative diseases, Sirt1 has been shown to decrease the 
accumulation of Tau protein and β-Amyloid peptide to prevent Alzheimer’s 
disease in mouse models. Sirt1 deacetylates and destabilizes Tau protein to 
prevent tangles in the Tau filaments, a leading causative agent of Alzheimer’s 
disease (Min et al., 2010). Sirt1 also deacetylates and activates transcription 
activator retinoic acid receptor β to transcribe α secretase which in turn 
channels the processing of amyloid precursor protein away from β-Amyloid 
peptide, preventing the accumulation of β-Amyloid peptide aggregate of 
plagues in the brain (Donmez et al., 2010). 
The role of Sirt1 in cancer has been one of dichotomous in nature, behaving 
either as a tumor suppressor or promoter. Sirt1 expression is elevated in 
cancers such as prostate cancer, colon cancer, non-melanoma skin cancers and 
acute myeloid leukemia; suggesting that Sirt1 may play a tumor promoter role 
in these cases (Huffman et al., 2007; Bradbury et al., 2005; Stunkel et al., 
2007; Hida et al., 2007). Inhibition of Sirt1 activity by Sirt1 inhibitor 
cambinol in BCL6- expressing Burkitt lymphoma induces apoptosis while 
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Sirt1 deficiency reduces chemoresistance to cisplatin in cancer cells, 
indicating that Sirt1 is vital for the survival of cancer cells (Heltweg et al., 
2006; Liang et al., 2008). 
Recently, more reports have surfaced indicating Sirt1 as a tumor suppressor.  
Deacetylation and inactivation of β-catenin by Sirt1 in adenomatous polyposis 
coli (APC) mutated transgenic mice reduces the occurrence of tumors 
compared to wildtype mice (Firestein et al., 2008). Sirt1 is down-regulated in 
BRCA1 associated breast cancers and Sirt1 overexpression decreases survivin 
expression by deacetylating H3K9 within the survivin gene promoter which 
encodes for the anti-apoptotic survivin, leading to growth inhibition of 
BRCA1 associated breast cancer cells (Wang et al., 2008; Altieri, 2008). In 
addition, transgenic mice heterozygous for both p53 and Sirt1 display high 
rates of tumor formation compared to p53 heterozygous mice despite reports 
of p53 being inactivated via deacetylation by Sirt1. This apparent increase in 
tumor incidence is explained by the inability of Sirt1 deficient mice in 
recruiting components of the DNA repair proteins such as RAD5 and NBS1 
upon DNA damage induction (Wang et al., 2008). These studies indicate Sirt1 
as a potential tumor suppressor. 
1.4.2. Sirt1 relation with p53 
p53 was identified as the first non-histone deacetylation target for Sirt1 (Luo 
et al., 2001). Sirt1 specifically deacetylates human p53 at lysine 382 (K382) 
(which corresponds to lysine 379 (K379) in mouse p53) on its C terminus 
(Luo et al., 2001 and Vaziri et al., 2001) provided the first evidence that 
deacetylation of p53 by Sirt1 modulates its growth arrest and apoptotic 
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functions while expression of catalytically inactive Sirt1 mutant results in 
hyperacetylated p53 and increased sensitivity to stress signals, highlighting the 
importance of the Sirt1-p53 relationship. 
As acetylation of p53 plays an important role in determining cell fates, the 
Sirt1-p53 pathway is tightly regulated. The activity and/or expression of Sirt1 
are under positive or negative regulation to control acetylation of p53.  
Several proteins associate with Sirt1 to increase its stability or p53 binding 
ability. The Ski protein physically associates with Sirt1 and increases the p53-
Sirt1 association resulting in p53 deacetylation and desensitization of cells to 
genotoxic stress. Suppression of Ski rescues the refractory nature of cells to 
genotoxic stress (Inoue et al., 2011). USP22 also functions a positive regulator 
of Sirt1 where it maintains its stability by cleaving away poly-ubiquitin 
conjugated to Sirt1. Inhibition of USP22 by RNA interference results in 
destabilization of Sirt1, enhanced p53 acetylation and elevated p53-dependent 
apoptosis (Lin et al., 2012). 
The negative regulation of Sirt1 activity on p53 acetylation is governed by 
several proteins and regulatory loops. The deacetylase activity and p53 
binding stability is negatively regulated by Mammalian Sterile 20 Like Kinase 
1 (MST1) and Deleted in Breast cancer 1 (DBC1). MST1, a serine/threonine 
kinase phosphorylates Sirt1. Phosphorylated Sirt1 has decreased activity and 
p53 association, leading to increased p53 acetylation and transactivation. On 
the other hand, DBC1 physically complexes with Sirt1 and prevents Sirt1 from 
binding to p53 and deactylating it. In addition, in vivo studies have 
demonstrated that elevated DBC1 mRNA levels in tumor tissues of lung 
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ademocarcinoma patients is positively correlated with increase in acetylated 
p53 expression, indicating a probable in vivo role of DBC1 in regulating p53 
acetylation in lung adenocarcinoma ( Zhao et al., 2008; Kim et al., 2008; 
Tseng et al., 2009). 
The Sirt1-p53 pathway is also controlled by regulatory loops. Methylated in 
cancer-1 (HIC1) is a transcriptional repressor that complexes with Sirt1 and 
binds to Sirt1 promoter to inhibit Sirt1 gene transcription. This in turn up-
regulates p53 acetylation. p53 continues to drive the positive feedback loop by 
transactivating HIC1, one of its target genes.  Alterations in the HIC1-Sirt1-
p53 regulatory loop through reduced HIC1 expression in human lung 
squamous cell carcinomas results in hypoacetylated p53 (Chen et al., 2005; 
Tseng et al., 2009). 
Recently, the non coding microRNA miR-34 was found to repress the 
transcription of Sirt1, leading to heightened p53 acetylation and activity. 
Incidentally, miR-34 encoding gene is a target of p53 transactivation creating 
a positive feedback loop where the miR-34 continuously fuel the stability of 
p53, and where p53 drives the transcription of miR-34 via the inhibition of 
Sirt1 transcription (Yamakuchi and Lowenstein, 2009). 
1.5. Perspectives and aims of studies 
Cellular senescence characterized by the irreversible cell cycle arrest of a cell 
is a critical cell fate phenomenon triggered by various types of intrinsic and 
extrinsic stresses (Itahana et al., 2004). The anti-proliferative nature of 
senescence demonstrated in various cancers indicates that cellular senescence 
is a tumor suppressive process. However, the resistance of some senescent 
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cancer cells to apoptosis induction have suggested a pro-survival role of 
senescence in carcinogenesis (Ohtani et al., 2012). 
A major regulator of the cellular senescence process is p53 which is activated 
by stress triggers of senescence. Activated p53 transactivates target genes 
involved in cell arrest to mediate the onset of cellular senescence. p53 itself is 
tightly regulated to prevent aberrant activation. Our laboratory reported Stra13, 
a basic helix-loop-helix transcription factor up-regulates p53 expression via 
physically interacting with p53 at the C terminus region, shielding p53 from 
ubiquitination (Thin et al., 2007). It is also reported that Stra13 is a p53 target 
and a mediator of p53 dependent cellular senescence (Qian et al., 2008). On 
the other hand, Sirt1, a NAD
+
 dependent histone deacetylase catalyses the 
deacetylation of p53 at lysine 379 of the mouse p53 (Luo et al., 2001; Vaziri 
et al., 2001). Deacetylation of p53 generally destabilizes and inactivates p53 
including its ability to induce senescence (Furukawa et al., 2007; Jang et al., 
2011). 
The independent studies of Stra13 and Sirt1 regulating the functions of p53 
post-transcriptionally seem to indicate antagonism of the two proteins in terms 
of p53 regulation where Stra13 seems to promote stability and presumably the 
activity of p53 while Sirt1 appears to deacetylate p53 and decrease its 
transcriptional function. Even though Stra13 and Sirt1 have not been studied 
together in relation to p53 regulation, a potential tripartite relationship of the 
three proteins may exist in biological setting where p53 mediated senescence 
may well be controlled via Sirt1 and Stra13. 
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We hypothesize that p53 mediated cellular senescence is regulated in an 
antagonistic manner by Sirt1 which functions as a negative regulator and 
Stra13 as a positive regulator of p53. Therefore, this research project aims to 
examine the potential antagonistic regulation mechanism of p53 by Sirt1 and 
Stra13. In addition, we investigated the role of Sirt1 in modulating Stra13-
mediated senescence that is p53-dependent. 
In the first part of the study, we demonstrated that Sirt1 physically interacts 
with Stra13 specifically at its basic helix-loop-helix motif. Stra13 positively 
mediates the p53 expression and acetylation at lysine 379. Knockdown of 
Sirt1 recapitulates the effect of Stra13 on p53 acetylation. The second part of 
the study demonstrates that Stra13 mediated senescence can be blocked by 
overexpression of Sirt1, or increase in Sirt1 activity. We further provide 
evidence that under cellular stress, the Sirt1-Stra13 and the Sirt1-p53 
associations are disrupted suggesting protein-protein interactions in regulating 










MATERIALS AND METHODS 
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2. Materials and Methods 
2.1. Cell Culture 
NIH3T3 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma Aldrich) supplemented with 10% bovine serum (Gibco), 3.7g/L 
sodium bicarbonate (Sigma Aldrich) and 1% penicillin-streptomycin (Sigma 
Aldrich). MEFs (kindly provided by Ms. Sumita Sethi) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) (Gibco), 3.7g/L sodium bicarbonate (Sigma Aldrich), 1% 
penicillin-streptomycin (Sigma Aldrich), 1% minimal essential medium 
(MEM) non-essential amino acids, 1% gentamicin and 0.02% 2-
mercaptoethanol. All cells were cultured in a humidified tissue culture 
chamber with 5% CO2 density at 37
o
C. 
2.2. DNA constructs  
pCS2-Myc-Stra13, GST-Stra13, His-Stra13 and its mutants (1-127, 127- 411) 
were previously described (Wang et al., 2012; Thin et al., 2007). pCDNA-
FLAG-Sirt1 was kindly provided by Dr. Martin J. Walsh (Mt Sinai School of 
Medicine, New York, NY10029). Plasmid pCMV-p53 was kindly provided by 
Dr. Bert Vogelstein (Howard Hughes Medical Institute, Chevy Chase, MD 
20815). 
2.3. Bacterial transformation 
100ng of plasmid DNA constructs was incubated with 50μl of DH5α 
competent cells (Invitrogen) on ice for 30 minutes prior to heat shock 
treatment at 42
o
C for 30 seconds. The cells was further incubated on ice for 2 
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minutes and then cultured with 500μl of Luria-Bertani (LB) broth for 1 hour at 
37
o
C with constant shaking at 250rpm. The cells in the LB broth were pelleted 
by centrifugation at 13000rpm for 1 minute and resuspended in 200μl of fresh 
LB broth and plated on LB agar plates supplemented with ampicillin 
(100μg/ml). The plates were then incubated overnight at 37oC to obtain 
bacterial colonies containing the transformed DNA plasmid constructs. 
2.4. DNA plasmid extraction from transformed bacterial cells 
Individual colonies of transformed bacterial cells were inoculated into 2ml of 
LB broth supplemented with ampicillin (100μg/ml) and incubated at 37oC for 
8 hours with constant shaking at 250rpm.  The bacterial culture was later 
scaled up to 300ml of LB broth supplemented with ampicillin (100μg/ml) and 
incubated overnight at 37
o
C with constant shaking at 250rpm. 
Bacterial cells from the overnight culture were pelleted by centrifugation at 
5000rpm for 5 minutes at 4
o
C. The supernatant was decanted and DNA 
plasmid extraction from the bacterial pellet was carried with Qiagen Plasmid 
Midi kit (Qiagen) according to manufacturer’s instruction. In summary, the 
bacterial pellet was resuspended in 4ml of P1 resuspension buffer (Rnase 
added) prior to the addition of 4ml of prechilled P2 lysis buffer which lysed 
the cells. The lysed cells were vigorously mixed and incubated at room 
temperature for 5 minutes. The mixture was neutralized with P3 neutralization 
buffer and vigorously mixed before incubation on ice for 15 minutes.  
The neutralized mixture was pelleted by centrifugation at 20,000rpm for 45 
minutes at 4
 o
C. During the centrifugation process, the Qiagen midi column 
was equilibrated with 4ml of QBT equilibration buffer. The supernatant was 
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decanted into the equilibrated Qiagen midi column and allowed to flow 
through by gravity. The column was washed twice with 10ml of QC wash 
buffer to remove contaminants from the filter in the column. DNA plasmid 
constructs retained on the filter of the column was eluted with 5ml of QF 
elution buffer and precipitated with 3.5ml of isopropanol. Precipitated DNA 
plasmid constructs were pelleted by centrifugation at 14,000rpm for 30 
minutes. The DNA pellet was washed with 70% ethanol and pelleted by 
centrifugation at 14,000rpm for 10 minutes. The ethanol was decanted and the 
DNA pellet was allowed to air dry. The DNA pellet was dissolved in 
appropriate amount of TE buffer (10mM Tris pH8, 1mM EDTA). The 
concentration of the dissolved DNA plasmid constructs was quantified with 
Nanodrop spectrophotometer (NanoDrop-1000, Thermo Scientific) and stored 
in -20
o
C for future usage. 
2.5. Transient transfection 
2.5.1. Transient tansfection of DNA plasmid constructs 
Adherent mammalian cells were seeded a day prior to transfection such that 
cell confluency is between 60 to 80% at the point of transfection. An 
appropriate amount of plasmid DNA constructs was transfected into the 
mammalian cells with Lipofectamine reagent (Invitrogen) according to 
manufacturer’s instructions. 
In summary, 4μg of DNA plasmid constructs for transfection of adherent 
mammalian cells in a single 10cm diameter tissue culture dish was diluted in 
300μl of DMEM not supplemented with serum or antibiotics (basal DMEM). 
15μl of Plus reagent (Invitrogen) was mixed with the diluted DNA and 
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incubated for 15 minutes. 300μl of basal DMEM containing 20μl of 
Lipofectamine reagent (Invitrogen) was mixed with the DNA mixture and 
incubated for an additional 15 minutes. During the incubation period, medium 
for the cells was changed to basal DMEM. The DNA mixture was added drop 
wise to the cells and incubated in a humidified tissue culture chamber with 5% 
CO2 density at 37
o
C for 4 hours. Cells were then cultured in serum containing 
DMEM for an additional 24 hours prior to lysis or further treatment. 
2.5.2. Transient tansfection of siRNA 
Adherent mammalian cells were seeded a day prior to transfection such that 
cell confluency is between 60 to 80% at the point of transfection. An 
appropriate amount of siRNA constructs was transfected into the mammalian 
cells with Lipofectamine RNAiMAX reagent (Invitrogen) according to 
manufacturer’s instructions. 
In summary, 500ρmol of siRNA for transfection of adherent mammalian cells 
in a single 10cm diameter tissue culture dish was diluted in 100μl of DMEM 
not supplemented with serum or antibiotics (basal DMEM). The types of 
siRNA utilized include control scrambled, Stra13, Sirt1 and p53 siRNA 
(Dharmacon; on-target plus smart pool). Sequences for siSirt1, sip53 and 
siStra13 are shown in Table II, Table III and Table IV, respectively. 45μl of 
RNAiMAX reagent (Invitrogen) was mixed with the diluted siRNA and 
incubated for 20 minutes. The siRNA mixture was added drop wise to the cells 
and incubated in a humidified tissue culture chamber with 5% CO2 density at 
37
o
C for 24 hours prior to lysis or further treatment. Knock down efficiency of 
the specific proteins was validated by western blotting. 
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2.6. Treatment of cells with chemicals 
2.6.1. Resveratrol: Sirt1 activator 
Resveratrol is a natural occurring polyphenol compound which activates Sirt1 
deacetylase activity (Howitz et al., 2003). Resveratrol (Sigma Aldrich) was 
dissolved in ethanol prior to usage. Adherent mammalian cells were grown to 
80% confluency at the point of resveratrol treatment. Titration of the dosage of 
resveratrol was carried out on these cells which were treated for 24 hours. 
2.5µM of resveratrol generated the optimal result which was used for the 
subsequent experiments. The acetylation status of lysine 379 in mouse p53 
was used as readout for the effect of resveratrol on Sirt1 deacetylase activity. 
Acetylation status of p53 was validated by western blotting. 
2.7. Genotoxic agents 
2.7.1. Cisplatin 
Cisplatin also known as Cis-diamminedichloroplatinum (CDDP) is a platinium 
containing compound which causes DNA cross-linking that is detected as 
DNA damage (Kovarik et al., 1972). Cisplatin (Sigma Aldrich) was dissolved 
in DMSO prior to usage. Adherent mammalian cells were grown to 80% 
confluency at the point of cisplatin treatment. Treatment of cells with 20μM of 
cisplatin (based on dosage used by Liu et al., 2011) was carried out for 24 
hours. The effect of cisplatin on p53 was validated by western blotting. 
2.7.2. Etoposide 
Etoposide is a topoisomerase inhibitor which causes disruptions in DNA 
replication forks formation resulting in the stalling of the DNA replication 
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process (Minocha and Long, 1984). Etoposide (Sigma Aldrich) was dissolved 
in DMSO prior to usage. Adherent mammalian cells were grown to 80% 
confluency at the point of etoposide treatment. Treatment of cells with 20μM 
of etoposide (based on dosage used by Liu et al., 2011) was carried out for 24 
hours. The effect of etoposide on p53 was validated by western blotting. 
2.8. Senescence assay 
The enhanced β-galactosidase activity in senescent cells was detected with 
Senescence Cells Histochemical Staining Kit (Sigma Aldrich) according to 
manufacturer’s instruction. In summary, cells were seeded at a confluency of 
3.5 x 10
3
 per well in six well tissue culture plates. The cells were cultured for 
seven days with medium change every alternate day. 
At day seven, the medium was aspirated and the cells were washed twice with 
1x PBS pH 6. The cells were then fixed on the plates with 1x fixation buffer 
for 6 minutes. During fixation, the staining buffer containing 1x staining 
solution, reagent B, reagent C and X gal was prepared. The fixation buffer was 
aspirated and cells were washed thrice with 1x PBS pH 6. Cells were finally 
incubated with the staining buffer for 24 hours at 37
o
C without a CO2 enriched 
environment. The senescent cells were visualized under light microscope and 
at least 300 cells were counted in total of five fields. The number of senescent 
cells was expressed in terms of percentage of senescent cells (stained blue) 





2.9. Immunofluorescence assay 
NIH3T3 Cells were cultured on coverslips (Thermonax) and co-transfected 
with Myc-Stra13 and FLAG-Sirt1 plasmid constructs for 24 hours. The 
Coverslips were washed thrice with 1x PBS and fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. Paraformaldehyde 
solution was aspirated and the coverslips were washed thrice with 1x PBS, 
prior to permeabilization of the cells with 0.5% Triton X for 10 minutes at 
room temperature. The coverslips were washed again with 1x PBS and 
incubated in blocking buffer (3% BSA) for 1 hour at room temperature.  
Cells were then incubated with primary antibodies mouse anti-Myc (Sigma 
Aldrich) 1:250 dilution and rabbit anti-Sirt1 (Merk Millipore), 1:250 dilution 
for 1 hour at room temperature and washed thrice with 1x PBS prior to 
incubation with Alexa Fluor 488 coupled with goat anti-mouse and goat anti-
rabbit IgG secondary antibody (Molecular Probes) 1:250 dilution for 1 hour at 
room temperature. Coverslips were washed thrice with 1x PBS and mounted 
with 2µl Vector shield mounting medium containing DAPI (Vector 
Laboratories). Immunofluorescence was visualized with a fluorescent 
microscope (Nikon Eclipse TE 2000-U) at 10X, 20X objective lens 
magnification and analyzed by Metamorph software version 7.0r3. 
2.10. Glutathione s-transferase (GST) pull-down Assay 
Escherichia coli BL21 cells were transformed with GST-Stra13 and GST 
DNA plasmid constructs and single transformed colonies were picked and 
cultured overnight at 37
o
C in 2ml of LB broth supplemented with ampicillin 
(100μg/ml). 1ml of overnight culture was scaled up to 100ml of LB broth 
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supplemented with ampicillin (100μg/ml) and grew at 30oC. Growth turbidity 
of the culture was measured by absorbance at 600nm wavelength in an hourly 
manner. 0.5mM IPTG was added to induce expression of GST-Stra13 and 
GST proteins when OD600 of the culture reached 0.8-1.0.  
Induction of the GST proteins expression was carried out for 3 hours and 
bacterial cells were pelleted by centrifugation at 5000rpm for 5 minutes. The 
bacterial pellet was resuspended with 10ml PBS solution (1% Triton X-100, 
0.1mM Dithiothreitol (DTT), complete protease inhibitor cocktail (Roche)).  
The bacterial cell suspension was lysed on ice by sonication (cycle on 5 
seconds/ off 5 seconds, 6 cycles with amplitude at 40) and incubated in ice for 
30 minutes. Cell debris was pelleted at 10000rpm for 10 minutes at 4
o
C and 
supernatant was incubated with glutathione sepharose 4B beads on a nutator 
for 30 minutes at 4
o
C. Glutathione sepharose 4B beads with bound GST-
Stra13 or GST proteins were sedimented by centrifugation at 2500rpm for 2 
minutes at 4
o
C. The beads were washed thrice with 1x PBS and reconstituted 
to a 50% slurry with 1x PBS supplemented with protease inhibitor. 
Quantification of GST-Stra13 and GST proteins were carried out with 
commassie blue staining of the proteins resolved by SDS-PAGE. 
FLAG-Sirt1 was in vitro translated using TNT-coupled reticulocyte lysate 
system (Promega) according to manufacturer’s instructions. In summary, 
12.5μg of FLAG-Sirt1 DNA plasmid construct was incubated with TNT-
coupled reticulocyte lysate system components which included rabbit 
reticulocyte lysate, reaction buffer, RNA polymerase, amino acid mixture and 
ribonuclease inhibitor. The mixture was incubated at 30
o
C for 90 minutes. 
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Expression of in vitro translated FLAG-Sirt1 was validated by western 
blotting.  
15µl of in vitro translated FLAG-Sirt1 was then incubated with 10µg GST or 
GST-Stra13 bound glutathione sepharose 4B beads in 200µl of binding buffer 
(50mM Tris-HCl pH8.0, 100mM NaCl, 0.3mM DTT, 10mM MgCl2, 0.1% 
NP-40, 10% glycerol, protease inhibitor cocktail) on a nutator at 4
o
C for 2 
hours. Beads were washed four times with binding buffer and resuspended in 
20µl of 1X SDS-PAGE loading buffer. Samples were denatured at 95
o
C for 6 
minutes and western blotted for Sirt1 and GST-Stra13. 
2.11. Protein extraction and protein quantification 
Adherent mammalian cells were washed with 1x PBS and dislodged from the 
tissue culture plate with 1x trypsin (1
st
 base) for 3 minutes at 37
o
C. The trypsin 
containing cells were neutralised with DMEM supplemented with serum. Cells 
were pelleted by centrifugation at 1200rpm for 5 minutes. The pellet cells 
were washed once with 1x PBS prior to lysis with RIPA lysis buffer (50mM 
NaCl (1
st
 base), 50mM Tris-HCl pH8 (1
st
 Base), 1mM EDTA (Sigma Aldrich), 
1% Triton X-100(USB), 0.05% SDS (1
st
 base), 0.1% sodium deoxycholate 
(Sigma Aldrich) and 1X  protease inhibitor (Roche)). Lysis was carried out 
with nutation at 4
o
C for 30 minutes. Cell debris was pelleted by centrifugation 
at 14,000rpm for 15 minutes at 4
o
C. The supernatant was collected and 
quantified using Braford protein assay (Biorad). 
The Braford protein assay reagent was diluted five times in water and 
aliquoted into 96-well plates at volumes of 200μl. 2μl of cell lysate was 
diluted in 38μl of water. 10μl of the diluted lysate was mixed with the braford 
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reagent in the 96-well plate and incubated for 5 minutes. This was done in 
duplicates. The absorbance of the braford reagent was measured by a 
microtiter spectrophotometer  (Bio-Tek Instuments, Inc) at wavelength 595nm. 
Calculation of the protein concentration of the lysate was based on comparing 
with protein standards measured previously in the similar manner.    
2.12. Co-immunoprecipitation 
500μg to 1000μg of cell lysate overexpressing Myc-Stra13 and FLAG-Sirt1 
was  incubated with 20µl of anti-Myc or anti-FLAG conjugated agarose beads 
(Sigma Aldrich) (prewashed twice with 1x PBS and once with RIPA lysis 
buffer) reconstituted in 500µl of RIPA lysis buffer supplemented with 1x 
protease inhibitor. The mixture was nutated overnight at 4
o
C. The beads with 
bound proteins were washed with RIPA lysis buffer where the beads were 
nutated at 4
o
C for 5 minutes each time and beads were pelleted 10000rcf for 
30 seconds. The washing step was repeated four times. The beads resuspended 
in 3x SDS-PAGE loading buffer and heated at 95
o
C to denature the proteins 
bound to the agarose beads. The beads were pelleted at 10000rcf for 30 
seconds and the supernatant was western blotted for the pulled down protein 
and its binding partner. 
2.13. Western blotting 
Cell lysates of the desired protein quantity was mixed with 1x SDS-PAGE 
loading buffer and heat denatured 95
o
C for 6 minutes. The proteins were 
resolved in an SDS-PAGE electrophoresis gel (8% - 12%). Once the desired 
separation of protein ladder markers (Biorad) was achieved, the resolved 
proteins in the SDS-PAGE electrophoresis gel were wet transferred onto a 
47 
 
nitrocellulose membrane (Amersham Hybond ECL, GE Healthcare) for a 
duration of 1.5 hours.  
The nitrocellulose membrane containing the transferred proteins was blocked 
with 5% skimmed milk dissolved in 1x PBST for 1 hour at room temperature. 
The nitrocellulose membrane was then incubated with the desired primary 
antibodies specific for the protein of interest at 4
o
C overnight. The 
nitrocellulose membrane was washed thrice for 5 minutes with 1x PBST prior 
to the addition of horse radish peroxidase (HRP) conjugated secondary 
antibodies diluted in 5% skimmed milk for 1 hour. After secondary antibody 
incubation, the nitrocellulose membrane was washed thrice for 5 minutes with 
1x PBST and the protein of interest was detected with chemiluminescence 
using ECL western blotting detection reagents (Amersham Biosciences GE 
Healthcare). The chemiluminescence was captured on X-ray film using the 
Kodak developer machine. 
2.14. Primary and secondary antibodies 
2.14.1. Primary antibodies 
Anti-FLAG (Sigma Aldrich, 1:1000); anti-Myc (Sigma Aldrich, 1:1000); anti-
ß-actin (Sigma Aldrich, 1:10,000); anti-Sirt1 (Millipore, 1:10,000); anti-p53 
(Santa Cruz Biotechnology, Inc. 1:500); anti-p53 Lys379 (Cell Signalling, 
1:500);  anti-Dec1 (Novus Biologicals. 1:500).  
2.14.2. Secondary antibodies 
Goat-anti-rabbit IgG (Sigma Aldrich, 1:5000) and goat-anti-mouse IgG 
(Sigma Aldrich, 1:5000). 
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2.15. RNA extraction and purification 
Total mRNA was extracted using TRIzol (Invitrogen) according to 
manufacturer’s instructions. Briefly, cells were harvested lysed with 1ml of 
TRIzol at room temperature for 5 minutes. 0.2ml of choloroform mixed 
vigorously with the cells for 15 seconds before incubation at room temperature 
for 2-3 minutes. Samples were then centrifuged at 12,000g at 4
o
C for 15 
minutes to obtain two phases: aqueous and organic. The aqueous phase was 
collected and RNA was precipitated by mixing it with 0.5ml of isopropanol 
and incubated at room temperature for 10 minutes. RNA was pelleted by 
centrifugation at 12,000g for 10 minutes at 4
o
C and washed with 1ml of 75% 
ethanol. RNA pellet was air dried and resuspended in DEPC water prior to 
storage at -20
o
C for further usage.  
2.16. Quantitative Real-Time Polymerase Chain Reaction (Q-PCR) 
cDNA was amplified using Lightcycler 480 SYBR Green 1 Master Kit 
(Roche). PCR mix for each sample was prepared in triplicates and loaded into 
Roche Light Cycler 480 (LC480) instrument according to manufacturer’s 
instructions. Light cycler 480 software (version 1.3.0.0705) was used for 
analysis. Primers specific to Sirt1, Stra13 and GAPDH are shown in Table V. 
2.17. Statistical  analysis 
All graphs in the results section show mean values with error bar indicates 
standard deviation (SD). Statistical significance was determined by two-tailed, 
un-paired Student’s t test and p values of <0.05 were considered to be 
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statistically significant. Different degrees of statistical significances were 













3. Results  
3.1. Stra13 modulates p53 expression and acetylation 
3.1.1. Stra13 increases p53 expression and acetylation in a dose dependent 
manner 
Previous studies from our lab have shown that Stra13 regulates p53 levels 
(Thin et al., 2007). Stra13 is able to increase p53 levels in dose dependent 
manner by preventing Mdm2 mediated ubiquitination of p53 and its 
subsequent nuclear export and degradation. Since acetylation of p53 has an 
impact on its ubiquitination by Mdm2, one possibility we considered is that 
cross talk with acetylation/deacetylation of p53 might underlie the effect of 
Stra13 on p53 levels. P53 is acetylated at six lysine residues at its C-terminus, 
and among them is K379 which is acetylated by histone acetyl transferase 
p300 and deacetylated by Sirt1. p53 deacetylation at K379 by Sirt1 is 
accompanied by modulation of p53 function (Luo et al., 2001; Vaziri et al., 
2001).  
In order to understand whether Stra13 impacts p53 acetylation at K379, 
NIH3T3 cells were co-transfected with a constant amount of p53 plasmid 
construct and increasing amounts of Myc-Stra13. Lysates were western blotted 
with anti-Myc, anti-p53 K379ac and anti-p53 antibodies. Consistent with our 
previous results (Thin et al., 2007), increasing Stra13 expression augmented 
p53 levels. Interestingly, levels of p53 acetylation at K379 positively 




Figure 3.1.1. Stra13 up-regulates p53 expression and acetylation. NIH3T3 
cells were co-transfected with constant amounts of p53 and increasing 
amounts of Myc-Stra13. Cell lysates were analyzed by western blot for p53 




3.1.2. Stra13 increases endogenous p53 expression and acetylation 
In order to validate these results, the expression levels and acetylation status of 
endogenous p53 was analyzed in the presence of Stra13. NIH3T3 cells were 
transfected with Myc-Stra13. Lysates were western blotted with anti-Myc, 
anti-p53 K379ac and anti-p53 antibodies. As predicted, over-expression of 
Stra13 up-regulated endogenous p53 levels and this was accompanied by 
increased acetylation of p53 at K379 which complemented the previous 













Figure 3.1.2. Stra13 increases endogenous p53 expression and acetylation. 
NIH3T3 cells were transfected with Myc-Stra13 or control vector plasmid. 
Cell lysates were analyzed by western blot for p53 acetylation at K379, total 
p53 and Myc-Stra13 expression. ß-actin was used as loading control. 
 
 
As p53 protein half life is highly regulated by post-translational modifications 
and acetylation of p53 generally promotes stability of the p53, increased 
acetylation at K379 might have enhanced the stability of p53 as depicted by 
increased p53 expression when Stra13 is over-expressed.   
Since Stra13 does not have known acetylation functions, the above results 
suggested Stra13 could have either enhanced acetylation activities of 
acetyltransferase or reduced the deacetylation process by deacetylases such as 
Sirt1 to affect p53 acetylation at K379 and ultimately its levels. Essentially, 
alteration of p53 K379 acetylation by Stra13 may provide a potential link 





3.1.3. Stra13 knockout MEFs have impaired p53 expression and 
acetylation 
Thin et al., 2007 demonstrated that Stra13 knockout thymocytes fail to up-
regulate p53 levels upon induction with genotoxic agents. However the 
acetylation status of endogenous p53 was not investigated. We thus were 
interested to analyze the effect of Stra13 deficiency on endogenous p53 and its 
acetylation at K379. 
To confirm the effect of Stra13 on p53 acetylation in vivo, we analyzed p53 
expression and acetylation at p53 K379 in MEFs. MEFs were isolated from 
wildtype and Stra13 null mice (kindly provided by Ms Sumita Sethi). MEFs 
were subjected to genotoxic stress in order to induce expression of 
endogenous p53. This was achieved through treatment of the cells with 20μM 
cisplatin for 24 hours and lysates were western blotted with anti-p53 K379ac 
and anti-p53 antibodies.  
Wildtype MEFs display a normal p53 response to genotoxic stress where p53 
expression and acetylation at K379 was induced. However, Stra13 -/- MEFs 
demonstrated decreased K379 acetylation and total p53 upon genotoxic stress 
induction as compared to wild MEFs, suggesting that Stra13 functioning as a 















Figure 3.1.3. Stra13 deficiency prevents p53 induction in MEFs. Stra13 
knockout and wildtype MEFs were treated with or without cisplatin (20µM) 
for 24 hours. Cell lysates were collected and analyzed by western blot for p53 
acetylation at K379 and total p53 expression. ß-actin was used as loading 
control.    
 
This result obtained under Stra13 deficient conditions when coupled with 
those obtained under Stra13 over-expression conditions demonstrates that 
endogenous Stra13 is important in mediating p53 K379 acetylation even 
though it does not have known acetyl-transferase activity.  
3.2. Stra13 mediated senescence is partially dependent on p53 
Having established a positive correlation of Stra13 expression with p53 K379 
acetylation and expression; and a regulatory pathway involving Stra13 up-
stream of p53, we proceed to investigate the biological relevance of the 
Stra13- p53 link.  
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The role of Stra13 and p53 in senescence has been reported. Stra13 has been 
considered as a marker of cellular senescence and Qian et al., 2008 reported 
that Stra13 is a target gene of p53 and it functions downstream of p53 to 
mediate p53-dependent senescence in MCF7 cells. This report suggests that 
p53 exists up-stream of Stra13.  
In order to examine the regulatory pathway of senescence in normal cells, we 
used NIH3T3 cells to analyze the ability of Stra13 to mediate senescence in 
cells containing or lacking p53. 
Endogenous p53 in NIH3T3 cells was knocked down with siRNA against p53 
prior to transfection with Myc-Stra13. Control cells were transfected with 
scrambled siRNA and transfected with Myc-Stra13. Validation of p53 
knockdown and Stra13 over-expression was carried out with western blotting 
of cell lysates with anti-p53 and anti-Myc antibodies. Transfected cells were 
cultured for seven days at low confluency before staining them for senescence 
using the Senescence Cells Histochemical Staining Kit. The stained 
senescence cells were visualized under light microscopy and quantified in 
terms of percentage of senescent cells relative to the total number of cells 
counted. 
As demonstrated previously, Stra13 over-expression positively regulated 
endogenous p53 expression levels. However, knock down of p53 diminished 
p53 levels induced by Stra13 (Figure 3.2a). Over-expression of Stra13 also 
induced senescence which was depicted as blue stained cells. This is 
consistent with known reports of the role of Stra13 in mediating senescence. 
In p53 siRNA cells senescence imposed by Stra13 over-expression was 
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reduced compared to control cells expressing scrambled siRNA and Myc-
Stra13. This was evident in the significant decrease in percentage of senescent 
cells of Stra13 over-expressing cells which are deficient in p53 as compared to 
Stra13 over-expressing cells containing normal levels of endogenous p53 
(Figure 3.2b and 3.2c). 
Our data suggests that Stra13 mediated senescence in NIH3T3 is p53 
dependent. However, as elimination of p53 does not fully abrogate senescence 
induced by Stra13, it is plausible that Stra13 may mediate senescence through 
p53-independent pathways. This findings are consistent with those reported by 
Qian et al., 2008 that p53 knockdown could only partially abrogate Stra13 
mediated senescence in MCF7 cells. The ability of Stra13 to mediate p53 in 























Figure 3.2. Stra13 mediated senescence is partially p53 dependent. (A) 
NIH3T3 cells were transfected with control vector or Myc-Stra13 plasmid. 
Endogenous p53 was knocked down with siRNA specific for p53. Scrambled 
siRNA was used as control. Cells were lysed and lysates were analyzed by 
western blot for the expressions of Myc-Stra13, p53 acetylation at K379 and 
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total p53. ß-actin was used as loading control. (B) Cells were seeded for 
senescence assays and cultured for 7 days prior to SA-ß-gal staining. (C) 
Quantification of percentage of SA-ß-gal positive cells was plotted in a bar 
chart. Error bars indicated standard deviations for triplicates for each sample. 
p-value was calculated using two-tailed, un-paired Student’s t test and the 
significance is shown [* is p < 0.05; ** is p < 0.01; *** is p < 0.001]. 
 
 
3.3. Sirt1 regulates Stra13 mediated p53 acetylation and senescence 
3.3.1. Increased Sirt1 activity down-regulates Stra13 mediated p53 
acetylation  
Results thus far indicated that acetylation of K379 of p53 which is a Sirt1 
deacetylation site is regulated by Stra13. This suggested that Sirt1 and Stra13 
may function in an antagonistic manner to regulate p53 K379 acetylation and 
its biological functions. 
In order to investigate the involvement of Sirt1 activity in the regulation of 
p53 by Stra13, NIH3T3 was co-transfected with a constant amount of p53 
expression construct and increasing amounts of Myc-Stra13 plasmid. In 
addition, endogenous Sirt1 activity was enhanced by treatment of transfected 
cells with 2.5μM resveratrol for 24 hours. The lysates were western blotted 
with anti-Myc, anti-p53 K379ac, anti-p53 antibodies. 
Over-expression of Stra13 increased both acetylated and total p53 in a dose 
dependent manner. However upon increased endogenous Sirt1 activity by 
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treatment with resveratrol, p53 K379 acetylation and total p53 were reduced as 
compared to the untreated cells (Figure 3.31).  
The above data provides preliminary evidence that regulation of endogenous 
Sirt1 activity can modulate Stra13 mediated increase in p53 levels and 
acetylation at K379, indicating that Stra13 and Sirt1 function in antagonistic 
manner in regulating p53 acetylation and expression. 
 
Figure 3.3.1. Increased Sirt1 activity modulates Stra13 mediated p53 
acetylation. NIH3T3 cells were co-transfected with constant amounts of p53 
and increasing amounts of Myc-Stra13. Cells were treated with 2.5uM 
resveratrol for 24 hour prior to lysis. Cell lysates were analyzed by western 
blot for p53 acetylation at K379, total p53 and Myc-Stra13 expression. ß-actin 
was used as loading control. 
 
 
3.3.2. Increased Sirt1 activity inhibits Stra13 mediated senescence 
Previously, we showed that Stra13 functions up-stream of p53 to mediate p53 
dependent senescence. This is also accompanied by increased p53 acetylation 
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at K379. In vitro assays also showed that p53 acetylation at K379 could be 
suppressed with increased Sirt1 activity. Other groups have also reported that 
Sirt1 could antagonize senescence induced by proteins such as promyelocytic 
leukemia protein (PML) and protein kinase CKII via deacetylation of p53 
(Langley et al., 2002; Jang et al., 2011). We thus investigated whether Stra13 
mediated senescence could be antagonized by Sirt1.  
NIH3T3 was transfected with Myc-Stra13 and treated with 2.5uM of 
resveratrol. Over-expression of Stra13 was validated by western blotting the 
lysates with anti-Myc antibodies. Lysates were also western blotted for anti-
Sirt1, anti-p53 K379ac and anti-p53 antibodies. Cells were then cultured for 
seven days before staining them for senescent cells.  
Western blot revealed that Stra13 over-expression increased p53 acetylation at 
K379 and total p53 levels. The increase in expression of p53 levels positively 
correlated with the increase in senescence obtained with over-expression of 
Stra13 compared to control cells. Resveratrol treatment did not alter 
endogenous Sirt1 expression but was able to down-regulate Stra13 mediated 
increase in p53 acetylation and expression. Moreover, enhancement of Sirt1 
activity by treatment with reseveratrol counteracted the ability of Stra13 to 
induce senescence as depicted by the decreased in percentage of senescent 
cells detected compared to Stra13 over-expressing cells not treated with 
resveratrol (Figure 3.3.2a, 3.3.b and 3.3.2c). The above experiment thus 
positions Sirt1 as a negative regulator of the Stra13-p53 regulatory pathway of 




























Figure 3.3.2. Resveratrol rescues Myc-Stra13 mediated cellular 
senescence. (A) NIH3T3 cells were transfected with Myc-Stra13 or control 
vector and cultured in the presence or absence of resveratrol (2.5µM) for 24 
hours. Cell lysates were analyzed by western blot for Myc-Stra13 expression. 
ß-actin was used as loading control. (B) Cells were seeded for senescence 
assays and cultured for 7 days prior to SA-ß-gal staining. (C) Quantification of 
percentage of SA-ß-gal positive cells was plotted in a bar chart. Error bars 
indicated standard deviations for triplicates for each sample. p-value was 
calculated using two-tailed, un-paired Student’s t test and the significance is 
shown [* is p < 0.05; ** is p < 0.01; *** is p < 0.001]. 
 
 
3.3.3. Sirt1 over-expression down-regulates Stra13 mediated p53 K379 
acetylation and senescence 
To further validate of the role of Sirt1 in regulating Stra13 mediated p53 K379 
acetylation and senescence, we examined the effect of Sirt1 over-expression. 
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NIH3T3 were co-transfected with FLAG-Sirt1 and Myc-Stra13 constructs. 
Lysates were western blotted with anti-Myc, anti-FLAG, anti-p53 K379ac and 
anti-p53 antibodies.  
Consistent with previous results, Stra13 over-expression up-regulated both 
endogenous p53 K379 acetylation and total p53 expression levels as compared 
to control transfected lysate. Co-expression of Sirt1 along with Stra13 resulted 
in reduced acetylated and total p53 levels compared to cells transfected with 
Stra13 alone (Figure 3.3.3a). These data provide further evidence that Sirt1 
antagonizes the ability of Stra13 to acetylate and increase expression of p53 
and further reinforced the inhibitory role of Sirt1 in Stra13 mediated 
regulation of p53. 
The effect of Sirt1 over-expression on Stra13 mediated senescence was also 
analyzed. In addition to quantifying the number of senescent cells, the degree 
of growth arrest (a characteristic of senescent cells) was also analyzed with 
colony forming assay. NIH3T3 cells co-transfected with FLAG-Sirt1 and/or 
Myc-Stra13 were cultured for seven days prior to staining the cell colonies 
with crystal violet to visualize them, or for β-galactosidase activity of 
senescent cells.  
Consistent with the previous reports from our lab (Sun et al., 2000; Wang et 
al., 2012), Stra13 over-expressing cells displayed significant growth arrest 
compared to control cells as depicted by decreased colony numbers and crystal 
violet dye uptake. Co-expression of Sirt1 and Stra13 blocked the growth 
arresting effect of Stra13 (Figure 3.3.3b and 3.3.3c). In addition, senescence 
induced by Stra13 over-expression was blocked by expression of Sirt1 (Figure 
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3.3.3d and 3.3.3e). Taken together, the senescence data and western blot 
analysis confirms the ability of Sirt1 in antagonizing both Stra13 mediated p53 

































Figure 3.3.3. Increased Sirt1 expression rescues Stra13 p53 acetylation, 
senescence and growth arrest. (A) NIH3T3 cells were co-transfected with 
FLAG-Sirt1 and Myc-Stra13. Cell lysates were analyzed by western blot for 
p53 acetylation at K379, total p53, FLAG-Sirt1 and Myc-Stra13 expression. ß-
actin was used as loading control. (B) Transfected cells were seeded for 
colony forming assay in triplicates and cultured for 14 days prior to 
visualization by staining with crystal violet dye. (C) Quantification of uptake 
of crystal violet by cells was plotted in a bar chart. Error bars indicated 
standard deviations for triplicates for each sample. p-value was calculated 
using two-tailed, un-paired Student’s t test and the significance is shown [* is 
p < 0.05; ** is p < 0.01; *** is p < 0.001]. (D) Cells were seeded for 
senescence assays and cultured for 7 days prior to SA-ß-gal staining. (E) 
Quantification of percentage of SA-ß-gal positive cells was plotted in a bar 
chart. Error bars indicated standard deviations for triplicates for each sample. 
p-value was calculated using two-tailed, un-paired Student’s t test and the 





3.3.4. Sirt1 knockdown partially rescues p53 K379 acetylation, p53 
expression and senescence in Stra13 deficient cells upon induction with 
cellular stress induction 
To validate these findings of antagonism between Sirt1 and Stra13 in 
regulating p53 acetylation and senescence, we examined the impact of 
knocking down both Sirt1 and Stra13 on p53 in response to genotoxic stress 
Both endogenous Sirt1 and Stra13 in NIH3T3 cells were simultaneously 
knocked down with siRNA. Cells with either Sirt1 or Stra13 knockdown 
individually were used as controls. Validation of Sirt1 and Stra13 knockdown 
was carried out with western blotting of the cell lysate with anti-Sirt1 and anti-
Stra13 antibodies. The siRNA transfected cells were subjected to genotoxic 
stress with etoposide treatment in order to induce the up-regulation of 
endogenous p53. Analysis of the expression levels of p53 and K379 
acetylation status of p53 also carried out by western blotting with anti-p53 
K379ac and anti- p53 antibodies.  
In addition, the siRNA transfected cells treated with and without etoposide 
were also cultured for analysis of senescence. 
As expected, scrambled control or Stra13 siRNA transfected NIH3T3 cells did 
not exhibit detectable levels of acetylated p53 or total p53 under non stress 
conditions. However, etoposide treatment triggered p53 expression in 
scramble siRNA transfected cells, but this response was muted in Stra13 
knockdown cells (Figure 3.3.4a). This is consistent with previous data in 
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Stra13 -/- MEFs treated with cisplatin, confirming that p53 expression is 
partially dependent on Stra13. 
In the absence of etoposide, knockdown of Sirt1 itself did not trigger an 
increase in acetylated p53 as compared to control cells. This could be 
explained by the fact that endogenous p53 is not induced and p53 expression 
might be too low in a non stress environment for western blot detection even 
though the knockdown of Sirt1 should have had increased acetylated p53 
levels (Figure 3.3.4a).  
The effect of Sirt1 knockdown was apparent in response to etoposide induced 
p53 expression which resulted in enhanced total p53 and p53 acetylation 
levels relative to cells treated with etoposide alone. Knockdown of Stra13 in 
Sirt1 deficient cells countered the increased p53 acetylation and total p53 
levels conferred by Sirt1 knockdown supporting the antagonism between 
Stra13 and Sirt1 in regulating p53 (Figure 3.34a).  
The senescence phenotype obtained from the Stra13 and Sirt1 knockdown 
cells was similar to the trend of p53 levels. Cells that were untreated with 
etoposide did not display signs of senescence. Upon etoposide treatment, 
scrambled siRNA transfected NIH3T3 cells underwent senescence. 
Knockdown of Sirt1 enhanced senescence compared to scrambled siRNA 
transfected cells while Stra13 deficiency partially reverted the effect exerted 
by Sirt1 knockdown (Figure 3.3.4b and Fig 3.3.4c). Both the analysis of p53 
levels and senescence occurrence indicated that endogenous Stra13 and Sirt1 
antagonized each other to regulate p53 levels and acetylation, as well as 


















Figure 3.3.4. Sirt1 knockdown partially reverts p53 K379 acetylation, p53 
expression and senescence in Stra13 deficient cells upon cellular stress. (A) 
NIH3T3 cells were co-transfected with siRNA specific for Sirt1 and Stra13. 
After 48 hours of transfection, cells were treated in the presence or absence of 
20µM etoposide for 2 hours prior to lysis. Cell lysates were analyzed by 
western blot for p53 acetylation at K379, total p53, FLAG-Sirt1 and Myc-
Stra13 expression. (B) Cells were seeded for senescence assays and cultured 
for 7 days prior to SA-ß-gal staining. (C) Quantification of percentage of SA-
ß-gal positive cells was plotted in a bar chart. Error bars indicated standard 
deviations for triplicates for each sample. p-value was calculated using two-
tailed, un-paired Student’s t test and the significance is shown [* is p < 0.05; 
** is p < 0.01; *** is p < 0.001]. 
 
 
3.4. Stra13 does not inhibit Sirt1 expression 
As Stra13 has been demonstrated to positively regulate p53 expression level 
and p53-dependent functions while Sirt1 seemed to counter the effect of 
Stra13, we were interested in determining the molecular mechanisms 
underlying this effect. Since Stra13 functions as a transcriptional repressor 
(Boudjelal et al., 1997; Sun et al., 2000; St Pierre et al., 2002; Wang et al., 
2012) we tested whether Stra13 represses Sirt1 expression through its 
transcriptional repression resulting in increased p53 K379 acetylation and 
senescence. 
In order to examine the effect of Stra13 on Sirt1 expression, Myc-Stra13 was 
transfected in NIH3T3 cells and lysates were western blotted with anti-Sirt1 
antibodies to analyze endogenous Sirt1 expression. Endogenous Sirt1 
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expression was unchanged even in the presence of Stra13, suggesting that 
Stra13 mediated p53 K379 acetylation does not occur due to the inhibition of 
endogenous Sirt1 expression (Figure 3.4).  
 
Figure 3.4. Stra13 does not inhibit Sirt1 expression. NIH3T3 cells were co-
transfected with FLAG-Sirt1 and Myc-Stra13. Cell lysates were analyzed by 




3.5. Sirt1 does not alter Stra13 transcription 
Sirt1 is a corepressor that can inhibit transactivation of target genes (Mulligan 
et al., 2011; Chanda et al., 2010). This is achieved through deacetylation of 
histones at the promoters by Sirt1. We thus investigated whether Sirt1 could 
played a role in negatively regulating Stra13 transcription, thus decreasing 
Stra13 mediated p53 K379 acetylation and expression. 
NIH3T3 was transfected in duplicates with FLAG-Sirt1 and the mRNA levels 
of endogenous Stra13 and over-expressed Sirt1 were analyzed via quantitative 
polymerase chain reaction assay (qPCR). Endogenous Stra13 mRNA was 
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unaltered with or without the presence of Sirt1 over-expression, thus 
excluding the possibility of Sirt1 repressing Stra13 mRNA levels in order to 








Figure 3.5. Sirt1 does not alter Stra13 transcription. NIH3T3 cells were 
transfected with FLAG-Sirt1 or control vector. Relative expressions of (A) 
FLAG-Sirt1 and (B) Stra13 mRNA were normalized to house-keeping gene 
GAPDH mRNA expression and plotted in bar chart. Error bars indicated 
standard deviations for triplicates for each sample. p-value was calculated 
using two-tailed, un-paired Student’s t test and the significance is shown [* is 




As neither Stra13 nor Sirt1 affected each other’s expression, we ruled out the 
possibility that regulation of p53 acetylation at K379 and senescence was 
mediated via transcriptional repression of either Sirt1 or Stra13. 
3.6. Stra13 mediated p53 acetylation at K379 and senescence is not Sirt1 
dependent 
Despite having excluded the repression of Sirt1 expression level by Stra13 
where it functions as a transcriptional inhibitor of Sirt1, Sirt1 may function 
down-stream of Stra13 where Stra13 could regulate Sirt1 activity instead of its 
expression. On the other hand, Sirt1 could also function up-stream of Stra13 
and regulated Stra13 function. 
 To examine the hierarchy between Sirt1 and Stra13, endogenous Sirt1 in 
NIH3T3 cells was knocked down with siRNA prior to transfection with Myc-
Stra13. Validation of Sirt1 knockdown and Stra13 over-expression was carried 
out with western blotting of the cell lysate with anti-Sirt1 and anti-Myc 
antibodies. Analysis of the expression levels of p53 and K379 acetylation 
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status of p53 was also carried out by western blotting with anti-p53 K379ac 
and anti- p53 antibodies. Transfected cells were also cultured for senescent. 
Interestingly, knockdown of Sirt1 did not alter the K379 acetylated p53 or 
total p53 levels in both Stra13 over-expressing and control cells. Stra13 over-
expressing cells with scrambled siRNA and those with siSirt1 displayed 
similar expression levels of p53 (Figure 3.6a). This was recapitulated in the 
senescence assay where no significant change was detected in the percentage 
of senescent cells between Stra13 over-expressing cells with or without Sirt1 
knockdown. These results suggest that Stra13 mediated p53 acetylation at 
K379 and senescence is not dependent on Sirt1 (Figure 3.6b and 3.6c). 
However, this does not rule out the possibility that Sirt1 could function up-
stream or parallel to Stra13 in regulating p53 and senescence. Moreover, 
control cells with Sirt1 knockdown also did not display increased p53 
acetylation or senescence as compared to control cells alone, suggesting that 
inhibition of Sirt1 expression could not mimic the effect of Stra13 over-













Figure 3.6. Stra13 mediated p53 acetylation at K379 and senescence is not 
Sirt1 dependent. (A) NIH3T3 cells were transfected with control vector or 
Myc-Stra13. Endogenous Sirt1 was knocked down with siRNA specific for 
Sirt1. Scrambled siRNA was used as control siRNA. Cells were lysed and 
lysates were analyzed by western blot for the expressions of Sirt1, Myc-Stra13, 
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p53 acetylation at K379 and total p53. ß-actin was used as loading control. (B) 
Cells were seeded for senescence assays and cultured for 7 days prior to SA-ß-
gal staining. (C) Quantification of percentage of SA-ß-gal positive cells was 
plotted in a bar chart. Error bars indicated standard deviations for triplicates 
for each sample. p-value was calculated using two-tailed, un-paired Student’s t 




3.7. Sirt1 associates with Stra13 
Up-regulation of Sirt1 expression or activity inhibits Stra13 dependent 
senescence. However, the regulatory mechanism does not involve 
transcriptional regulation as neither Stra13 nor Sirt1 regulate each other’s 
expression to elicit their antagonistic effects on p53. This suggests alternative 
regulatory mechanisms such as activity modulation or/and protein- protein 
interaction. We therefore proceeded to further define the regulatory 
mechanism of Sirt1 and Stra13 on p53. 
Sirt1 has been shown to physically interact with bHLH-O members such as 
Hes1 and Hey2 to mediate transcriptional repression of Hes1 and Hey2 genes 
(Takata and Ishikawa, 2003). In addition, Sirt1 interacts with Sharp-1, a 
member of the bHLH-O subfamily. However, the functional relevance of this 
interaction is unknown (Fugimoto et al., 2007). The above reports suggested 
that Sirt1 may interact with Stra13 which is also a bHLH-O member to 





3.7.1. Sirt1 co-immunoprecipitates with Stra13. 
We first tested whether Stra13 can interact with Sirt1 by co-
immunoprecipitation assays. NIH3T3 cells were co-transfected with FLAG-
Sirt1 and Myc-Stra13. Cell lysates were immunoprecipitated with anti-FLAG 
antibody conjugated agarose beads and western blotted with anti-FLAG and 
anti-Myc antibodies. Immunoblot analysis revealed that FLAG-Sirt1 co-
immunoprecipitated with Myc-Stra13, indicating in vitro physical association 
of Sirt1 with Stra13 (Figure 3.7.1). 
 
Figure 3.7.1. Sirt1 co-immunoprecipitates with Stra13. Myc-Stra13 and 
FLAG-Sirt1 were co-transfected in NIH3T3 cells. Cells were lysed and lysates 
were analyzed by western blot for FLAG-Sirt1 and Myc-Stra13 expression. β-
actin was used as loading control. Immunoprecipitation of FLAG-Sirt1 was 
carried out with anti-FLAG conjugated agarose beads. The presence of co-






3.7.2. Sirt1 co-localizes with Stra13 in the nucleus. 
Previous studies from our lab showed that Stra13 localized in the nucleus both 
in the absence and presence of DNA damaging agents (Thin et al., 2007) 
while Sirt1 has been reported to have nucleocytoplasmic shuttling capability 
(Tanno et al., 2007) where both nuclear and cytoplasmic localizations of Sirt1 
have been reported (Donmez et al., 2010; Jin et al., 2007).  
To examine whether Stra13 could co-localize with Sirt1, NIH3T3 cells were 
co-transfected with FLAG-Sirt1 and His-Stra13 constructs prior to fixation. 
Transfected cells were probed with anti-FLAG and anti-His antibodies. 
Fluorescent secondary antibodies against anti-FLAG and anti-Histidine 
antibodies were used to visualize transfected proteins. The nucleus of the cell 
was stained with DAPI. Co-localization data demonstrated that transfected 
FLAG-Sirt1 and His-Stra13 reside in the nucleus (Figure 3.7.2). 
 
Figure 3.7.2. Stra13 and Sirt1 co-localized in the nucleus. NIH3T3 cells 
were co-transfected with Myc-Stra13 and FLAG-Sirt1. Co-localization of 
Stra13 and Sirt1 was analyzed by immunofluorescence staining using anti- 
Myc antibody (red) and anti-FLAG antibody (green). Nuclei were stained with 
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DAPI (blue). The images were merged and co-localization of these proteins 
was visualized by yellow fluorescence. Images were captured under a 
microscope with 20x magnification. 
 
 
3.7.3. Sirt1 directly interacts with Stra13 
To examine if the association between Stra13 and Sirt1 is direct, glutathione S 
transferase (GST) beads pull down assay were carried out. GST-Stra13 (Sun & 
Taneja, 2000) and GST alone were induced in Escherichia coli BL21 by the 
addition of IPTG. GST-Stra13 was purified from the bacterial lysate via pull 
down with glutathione sepharose 4B beads. GST-Stra13 protein was isolated 
and resolved on an SDS-PAGE gel and stained with commassie blue. The 
resolved GST-Stra13 was quantified with BSA standards. Sirt1 was in vitro 
transcribed and translated using the TNT-coupled reticulocyte lysate system. 
In vitro translated Sirt1 was incubated with equivalent amounts of GST Stra13 
or GST alone as a control. Proteins bound to glutathione sepharose 4B beads 
were resolved and western blotted with anti-FLAG antibodies. Result 
confirmed that Stra13 interacted directly with Sirt1, whereas as expected no 






Figure 3.7.3. Stra13 directly interacts with Sirt1. In vitro translated FLAG-
Sirt1 was incubated with glutathione sepharose 4B beads bound with GST or 
GST-Stra13 fusion proteins. The presence of bound FLAG-Sirt1 was analyzed 
by western blot. 10% of FLAG-Sirt1 was used as input. 
 
 
3.7.4. Sirt1 associates with a region containing the bHLH motif of Stra13 
Sirt1 is known to interact with bHLH proteins Hes1 and Hey2 specifically 
through the basic helix-loop-helix domain (Takata et al., 2003). Similarly, 
Sharp-1, a protein highly related to Stra13 which shares 97 % homology with 
the bHLH motif in Stra13 has also been demonstrated to interact with Sirt1 
through this bHLH domain (Fujimoto et al., 2007). These reports suggest that 
Sirt1 and Stra13 interaction may also occur via the bHLH motif. 
In order to investigate this possibility and pinpoint the specific domains in 
which Sirt1 and Stra13 interact, co-immunoprecipitation of Stra13 deletion 
mutants and Sirt1 were conducted. Two Stra13 deletion mutants used (Sun & 
Taneja, 2000) namely His-Stra13 (1-127) which contains the bHLH domain, 
and His-Stra13 (111-411) that lacks the bHLH domain (Figure 3.7.4a). 
NIH3T3 cells were co-transfected with full length or STra13 deletion mutants 
together with FLAG-Sirt1. Lysates were immunoprecipitated with anti-
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Histidine antibody conjugated beads prior to western blotting with anti-FLAG 
and anti-Histidine antibodies. As demonstrated in previous results, full length 
Stra13 interacted with Sirt1. His-Stra13 (1- 127) which contains the bHLH 
motif also interacted with Sirt1. However, the deletion of the bHLH motif in 
His-Stra13 (111- 411) disrupted the binding between Sirt1 and Stra13. Results 
indicated that Stra13 interacted with Sirt1 through a region containing its 

















Figure 3.7.4. Sirt1 interacts with a region containing the bHLH motif of 
Stra13.  (A) Schematic representation of full-length Stra13 (1-411) and its 
deletion mutants. (b, basic region; HLH, helix-loop-helix domain; O, orange 
domain.) (B) NIH3T3 cells were co-transfected with full length His-Stra13 or 
its mutants (showed in A) and FLAG-Sirt1. Cell lysates were analyzed by 
western for His-Stra13, its mutants and FLAG-Sirt1 expression. ß-actin was 
used as loading control. Lysates were immunoprecipitated with anti-His 
conjugated agarose beads. The presence of co-immunoprecipitated FLAG-
Sirt1 was analyzed by western blot. 
 
 
Interestingly, Stra13 also interacts with p53 through the bHLH domain of 
Stra13 (Thin et al., 2007). Taken together, the findings of association of Stra13 
with Sirt1, and Stra13 with p53, seem to highlight the N-terminus region 
containing the bHLH domain of Stra13 as a potential physical bridge linking 
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the three proteins. The bHLH domain might also be playing a pivotal 
regulatory role in terms of the how the three proteins could function as a 
complex in regulation of biological activities. 
3.8. Sirt1 deacetylates Stra13 
Besides functioning as a deacetylase of p53 at K379, Sirt1 has also been 
reported to deacetylate other proteins such as FOXO subclass of transcription 
factors and p300, a histone acetyltransferase that acetylates p53 at K379 
(Brunet et al., 2004; Hariharan et al., 2010; Bouras et al., 2005). In particular, 
the repression of p300 activity by Sirt1 mediated deacetylation is thought to 
act as an alternative pathway preventing acetylation of p53 at K379 which 
complements the direct deacetylation of p53 K379 by Sirt1 (Bouras et al., 
2005). In a similar manner to p300 relationship to p53 and Sirt1, Stra13 also 
mediates acetylation of p53 and is able to associate with Sirt1. The possibility 
of Sirt1 deacetylates Stra13 to inhibit its effect on p53.  
We tested if Stra13 is a deacetylation target of Sirt1. NIH3T3 cells were co-
transfected with FLAG-Sirt1 and Myc-Stra13. Cell lysates were 
immunoprecipitated with anti-acetyl lysine antibody conjugated agarose beads 
and western blotted with anti-Myc antibody. Western blot analysis revealed 
that in the presence of Sirt1, immunoprecipitated Stra13 exist in a deacetylated 
form compared to Stra13 transfected control lysates (Figure 3.8). This 
indicates that Stra13 is likely a deacetylation target of Sirt1. Deacetylated 
Stra13 could potentially have decreased activity and muted its ability to 
mediate p53 acetylation. However, this link between deacetylated Stra13 and 




Figure 3.8. Sirt1 deacetylates Stra13. Myc-Stra13 and FLAG-Sirt1 were co-
transfected in NIH3T3 cells. Cells were lysed and lysates were analyzed by 
western blot for FLAG-Sirt1 and Myc-Stra13 expression. β-actin was used as 
loading control. Immunoprecipitation of proteins acetylated at lysine residues 
was carried out with anti-N acetyl lysine antibody conjugated agarose beads. 




3.9. p53 regulation by Sirt1 and Stra13 is via protein-protein interaction  
3.9.1. p53 interaction with Stra13 or Sirt1 are not disrupted with 
introduction of Sirt1 and Stra13 respectively 
Since we ruled out transcriptional regulation as a regulatory mechanism 
utilized between Stra13 and Sirt1 in modulating each other’s expression, the 
possibility of protein-protein interactions between Sirt1, Stra13 and p53 was 
investigated. 
We tested two possibilities (1) Sirt1 may competitively disrupt the association 
of Stra13 and p53 that may then allow for the occurrence of Sirt1-p53 
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interaction and subsequent deacetylation of p53 by Sirt1. (2) Stra13 may 
disrupt Sirt1-p53 binding by strengthening its association with p53 to prevent 
deacetylation of p53. 
In order to test the above hypothesis, NIH3T3 cells were co-transfected with 
p53 and Myc-Stra13. In addition, FLAG-Sirt1 was also co-transfected to 
check if it could disrupt the binding between p53 and Stra13. Cell lysates were 
immunoprecipitated with anti-Myc antibody conjugated agarose beads and 
western blotted with anti-Myc and anti-p53 antibodies. Western blot analysis 
revealed that p53 co-immunoprecipitated with Myc-Stra13, but expression of 
Sirt1 did not alter this association (Figure 3.9.1a). 
The ability of Stra13 to disrupt Sirt1 and p53 association was also tested. 
NIH3T3 cells were co-transfected with p53 and FLAG-Sirt1. Myc-Stra13 was 
co-transfected and the binding between p53 and Sirt1 was examined. Cell 
lysates were immunoprecipitated with anti-FLAG antibody conjugated 
agarose beads and western blotted with anti-FLAG and anti-p53 antibodies. 
Western blot analysis revealed that Stra13 did not impact the association of 












Figure 3.9.1. p53 interaction with Stra13 or Sirt1 are not disrupted with 
introduction of Sirt1 and Stra13 respectively. (A) NIH3T3 cells were co-
transfected with Myc-Sharp-1 and p53 in either the presence or absence of 
FLAG-Sirt1. Cell lysates were analyzed by western blot for p53, FLAG-Sirt1 
and Myc-Stra13 expression. ß-actin was used as loading control. Lysates were 
immunoprecipitated with anti-FLAG conjugated agarose beads and the 
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presence of co-immunoprecipitated p53 was analyzed by western blot. (B) 
NIH3T3 cells were co-transfected with FLAG-Sirt1 and p53 in either the 
presence or absence of Myc-Stra13. Cell lysates were analyzed by western 
blot for p53, FLAG-Sirt1 and Myc-Stra13 expression. ß-actin was used as 
loading control. Lysates were immunoprecipitated with anti-Myc conjugated 
agarose beads and the presence of co-immunoprecipitated p53 was analyzed 
by western blot. 
 
 
Both studies seemed to indicate that under normal cellular conditions, the 
binding of p53 to either Sirt1 or Stra13 was not altered in the presence of 
Stra13 or Sirt1 respectively. We further investigated association of the three 
proteins under stress conditions by subjecting transfected cells to etoposide 
treatment prior to co-immunoprecipitation.  
3.9.2. Stra13 dissociates from Sirt1 under stress conditions 
Sirt1 can counteract Stra13 mediated p53 acetylation and cellular senescence 
indicating that Sirt1 inhibits Stra13 activity. We examined whether this 
inhibitory effect on Stra13 exerted by Sirt1 is achieved through protein- 
protein interactions that are altered under genotoxic stress that promote 
Stra13-mediated increase in acetylated p53. 
Thus, we tested the interaction of Sirt1 with Stra13 upon treatment with 
etoposide, a DNA damaging drug which is reported to induce senescence and 
Stra13 expression. Prior to etoposide treatment, NIH3T3 cells were co-
transfected with FLAG-Sirt1 and Myc-Stra13. Cell lysates were 
immunoprecipitated with anti-FLAG antibody or anti-Myc antibody 
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conjugated agarose beads and western blotted with anti-Myc or anti-FLAG 
antibodies. Western blot analysis revealed that Stra13-Sirt1 interaction was 
weakened in either of the pull down assays when cells were subjected to 
etoposide treatment (Figure 3.9.2). The dissociation of Sirt1 from Stra13 may 
alleviate the inhibition of Stra13 and allow for Stra13-mediated increase in 
p53 acetylation and senescence to occur. 
 
Figure 3.9.2. Stra13 dissociates from Sirt1 under stress conditions. Myc-
Stra13 and FLAG-Sirt1 were co-transfected in NIH3T3 cells. After 24 hours 
of transfection, cells were treated in the presence or absence of 20µM 
etoposide for 2 hours prior to lysis. Cells were lysed and lysates were analyzed 
by western blot for FLAG-Sirt1 and Myc-Stra13 expression. β-actin was used 
as loading control. Immunoprecipitation of Myc-Stra13 was carried out with 
anti-Myc conjugated agarose beads. The presence of co-immunoprecipitated 






3.9.3. Stra13-p53 association strengthens under stress conditions 
We then examined whether Stra13 association with p53 is enhanced under 
genotoxic stress which could further promote p53 stabilization.  
NIH3T3 cells were co-transfected with p53 and Myc-Stra13. Cell lysates were 
immunoprecipitated with anti-Myc antibody conjugated agarose beads and 
western blotted with anti-Myc or anti-p53 antibodies. Western blot analysis 
revealed that Stra13-p53 interaction was strengthened when cells were 
subjected to etoposide treatment (Figure 3.9.3). These results suggest that an 
increased association of Stra13 with p53 under stress condition may be critical 
for the heightened p53 acetylation and expression in the presence of Stra13. 
 
Figure 3.9.3. Stra13-p53 association strengthens under stress conditions. 
Myc-Stra13 and p53 were co-transfected in NIH3T3 cells. After 24 hours of 
transfection, cells were treated in the presence or absence of 20µM etoposide 
for 2 hours prior to lysis. Cells were lysed and lysates were analyzed by 
western blot for p53 acetylation at K379, total p53 and Myc-Stra13 expression. 
β-actin was used as loading control. Immunoprecipitation of Myc-Stra13 was 
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carried out with anti-Myc conjugated agarose beads. The presence of co-
immunoprecipitated p53 was analyzed by western blot. 
 
 
3.9.4. Sirt1 dissociates from p53 under stress conditions 
We have previously demonstrated that Stra13 dissociates from Sirt1 while its 
association with p53 is strengthened under genotoxic stress conditions.  
However, whether Sirt1 remains bound to p53 under these conditions is 
unknown. Since p53 is the first non-histone deacetylation target for Sirt1 
where it directly binds to p53 and specifically deacetylates p53 at K379 on its 
C terminus (Luo et al., 2001 and Vaziri et al., 2001) and etoposide treatment 
increases p53 acetylation, it suggests that the ability of Sirt1 to bind and 
deacetylate p53 may be counteracted by genotoxic stress.  
To test the above, NIH3T3 cells were co-transfected with p53 and FLAG- 
Sirt1. Cell lysates were immunoprecipitated with anti-FLAG antibody 
conjugated agarose beads and western blotted with anti-FLAG or anti-p53 
antibodies. Western blot analysis revealed that Sirt1-p53 interaction was 
weakened when cells were subjected to etoposide treatment, suggesting that 
increase in p53 K379 acetylation might be due to the dissociation of Sirt1 
from p53 during stress, rendering Sirt1 deacetylation activity ineffective on 




Figure 3.9.4. Sirt1 dissociates from p53 under stress conditions. FLAG-
Sirt1 and p53 expression vector were co-transfected in NIH3T3 cells. After 24 
hours of transfection, cells were treated in the presence or absence of 20µM 
etoposide for 2 hours prior to lysis. Cells were lysed and lysates were analyzed 
by western blot for p53 acetylation at K379, total p53 and FLAG-Sirt1 
expression. β-actin was used as loading control. Immunoprecipitation of 
FLAG-Sirt1 was carried out with anti-FLAG conjugated agarose beads. The 















Cellular senescence is a stress response that suppresses the development of 
cancers by permanently arresting proliferation of cells that have experienced 
damage or other stimuli that may place them at risk for malignant 
transformation.  Previous studies have reported p53 as a central regulator of 
senescence (Di Leonardo et al., 1994; Parrinello et al., 2003; Serrano et al., 
1997). Qian et al., 2008 demonstrated that Stra13, a bHLH transcription factor 
is a transcriptional target of p53 and it functions downstream of p53 to 
mediate cellular senescence in MCF7 cells. In addition, our laboratory 
reported that Stra13 positively regulates p53 expression via preventing the 
ubiquitination and subsequent degradation of p53 (Thin et al., 2007). 
On the other hand, Sirt1 is a NAD
+ 
dependent histone deacetylase that 
catalyses the deacetylation of mouse p53 at K379 (Luo et al., 2001 and Vaziri 
et al., 2001). Deacetylation of p53 generally destabilizes and inactivates p53 
including its ability to induce senescence. Therefore we postulated that Sirt1 
may antagonize Stra13 in terms of regulating p53 functions. 
In this study, we demonstrate that Stra13 induces senescence in NIH3T3 cells 
and this is a p53-dependent process. We also show Stra13 positively mediates 
p53 acetylation at K379 which is a Sirt1 deacetylation site. The increase in 
p53 acetylation correlates with the up-regulation of p53 expression reported 
previously (Thin et al., 2007). Previous studies shown that p53 induced 
senescence is dependent on Stra13 as it is a down-stream mediator of p53 in 
MCF7 cells (Qian et al., 2008). The difference in regulatory hierarchy 
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between p53 and Stra13 described here and Qian et al., 2008 can be explained 
in several ways which will be discussed in later sections. 
As Stra13 mediates the increases in acetylation of K379 of p53 which is also a 
deacetylation site for Sirt1, we examined the role of Sirt1 in antagonizing the 
effect of Stra13 on p53 and thus modulate p53 functions. Induction of 
endogenous Sirt1 activity with resveratrol suppressed Stra13 mediated p53 
acetylation and expression. Moreover, over-expression of Sirt1 also had 
identical effects on p53 acetylation and expression as compared to Sirt1 
activity modulation by resveratrol. Consistent with these effects, we also saw 
this impact of Sirt1 on Stra13 induced senescence. Thus increased Sirt1 
activity or expression reduced Stra13-mediated senescence. Interestingly 
however, loss of Sirt1 expression using siRNA in Stra13 over-expressing cells 
did not impact Stra13 dependent p53 expression and senescence. These data 
suggest that Sirt1 is not a downstream effector of Stra13. 
To further confirm the antagonism between Stra13 and Sirt1 in regulation of 
p53, a double knock down approach was used. We demonstrate that under 
genotoxic stress, Sirt1 knock down in Stra13 deficient cells counteracts the 
effect of Stra13 knockdown on p53 induction. Taken together, we proved that 
Stra13 and Sirt1 antagonize each other in the regulation of p53 acetylation and 
senescence. 
To unravel the mechanisms behind the regulation of p53 by Sirt1 and Stra13, 
we examined the possibility of transcriptional repression of Stra13 by Sirt1 
and conversely transcriptional repression of Sirt1 by Stra13. However, 
transcription of neither gene was regulated by the other. These data indicated 
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other mechanism may explain the antagonism between Sirt1 and Stra13 in 
regulation of p53. 
Previous studies by our laboratory demonstrated that Stra13 could physically 
associate with p53 via the bHLH motif (Thin et al., 2007). Others have 
reported the association of Sirt1 with p53 (Luo et al., 2001 and Vaziri et al., 
2001). These studies suggest that all three proteins may exist as a complex to 
regulate p53. Through binding and localization assays we show that Sirt1 and 
Stra13 physically interact. Stra13 is also deacetylated by Sirt1 in vitro, 
however the biological relevance of this is yet to be investigated. 
Expression of Sirt1 did not disrupt the p53-Stra13 interaction, and conversely, 
Stra13 did not alter p53-Sirt1 interaction. However, in presence of etoposide 
which activates p53, the interactions of Sirt1 with Stra13 and p53 were 
weakened, while the association of Stra13 and p53 was enhanced. Our 
findings provide a potential mechanism for regulation of cellular senescence 
via modulation of p53 activity and ultimately p53 mediated senescence 




Figure 4. Proposed model for regulation of p53 dependent senescence by 
Stra13 and Sirt1. Under normal conditions, Sirt1 maintains p53 in a 
deactylated form. This inhibits the onset of senescence. However, under stress 
conditions, Sirt1 dissociates from p53 while Stra13 association with p53 is 
enhanced. Stra13 mediates p53 acetylation at lysine 379 and drives the onset 
of premature senescence. 
 
4.2. The mechanistic hierarchy of Stra13 and p53 
As mentioned earlier, there are currently two fields of thoughts regarding the 
regulatory relationship between Stra13 and p53. Our laboratory previously 
showed that Stra13 is able to enhance p53 amounts via an Mdm2 dependent 
manner (Thin et al., 2007). This experiment has been also been faithfully 
reproduced in this thesis. K379 acetylated form of p53 is also shown to be 
upregulated in a dose dependent manner by Stra13 (Figure 3.1.1). In addition, 
Stra13 null MEFs fail to upregulate endogenous p53 levels upon genotoxic 
stress treatment. These data indicates Stra13 as regulator of p53. 
On the other hand, Qian et al., 2008 demonstrated the presence of p53 
responsive elements in the Stra13 promoter. Stra13 expression is induced by 
p53 overexpression. Stra13 is also able to induce senescence in MCF7 cells 
deficient in p53, suggesting a downstream role of Stra13 in p53 mediated 
responses. (Qian et al., 2008). 
The underlying reason for the apparent contradictory data presented by the 
two groups could be speculated to be the cause of different cellular models 
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utilized in the studies. A more thought provocative explanation for the Stra13-
p53 hierarchy would be the existance of a Stra13-p53 positive feedback loop. 
Upon closer scrutinization, both groups did not explicitly exclude the 
possibility of a reversal of the Stra13-p53 hierarchy being proposed. The 
induction of Stra13 expression by genotoxic and radiation stresses 
demonstrated by Thin et al., 2007 could well be a result of transcription of 
Stra13 gene mediated by p53 which are known to be elevated under these 
stress conditions (Thin et al., 2007). 
On the other hand, even though Stra13 could induce premature senescence in 
p53 knock down MCF7 cells, the extent of senescence was much weaker than 
in p53 proficient MCF7 cells. It is hypothesized by Qian et al., 2008 that p53-
Stra13 relationship may function in a similar manner to that of p53 and 
promyelocytic leukemia protein (PML) where p53 positively regulates PML 
expression and in turn PML induces senescence by stabilizing p53 (Qian et al., 
2008). This suggests p53 may also have an important role downstream of 
Stra13 during senescence, reinforcing the plausible presence of a Stra13-p53 
positive feedback loop. 
In this proposed Stra13-p53 positive feedback loop, p53 positively regulates 
Stra13 transcription. In turn, Stra13 protein would mediate p53 stability via 
promoting acetylation of p53 also shielding it from Mdm2 ubiqitination and 
subsequent degradation, The proposed model of Stra13-p53 regulation would 





4.3. p300/CBP , the potential link to Stra13 mediated p53 acetylation 
The level and activity of p53 are primarily regulated through post translational 
modifications. p53 acetylation, a form of post translation modification is a 
tightly regulated event that has been linked to p53’s stability and 
transactivation status in response to cellular stresses (Pearson et al., 2000 and 
Ito et al., 2001). Under normal physiological conditions, p53 is kept at steady 
state basal levels by the E3 ubiquitin ligase, MDM2 where it remains in a 
deacetylated form. p53 inducing events would relief the MDM2 inhibition on 
p53 and promote its acetylation (Mommard et al., 1992 and Ito et al., 2001). 
One such p53 inducing event is the introduction of Stra13 in NIH3T3 cells as 
demonstrated by the thesis. Stra13 mediates the p53 K379 acetylation and 
expression. However, Stra13 do not have known acetyl transferase function  
and this would have implied that Stra13 could have recruited acetyl 
transferases to mediate p53 K379 acetylation. Since K379 acetylation of p53 is 
exclusively mediated by p300/CBP (Ito et al., 2001), Stra13 would most likely 
have functioned in cooperation with p300/CBP to acetylate p53 and mediate 
senescence. Thus it would be vital to investigate the Stra13-p300/CBP link 
further complete the Stra13-p53-Sirt1 mechanisms being proposed. 
4.4. Interplay of acetylation and ubiquitination 
In the study of Stra13 effect on p53 post-translational modification, Stra13 is 
demonstrated to physically interact with p53 and shield it from MDM2 
mediated ubiquitination and nuclear export, thereby upregulating p53 levels. 
In addition, we have also shown that Stra13 could mediate the p53 K379 
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acetylation and thus stabilizing p53. On the other end of the spectrum, Sirt1 
counteracts the acetylation of p53 K379 and destabilizes p53 levels. 
All three separate studies seem to indicate an intimate interplay between the 
acetylation and ubiquitination status of p53. Indeed, p53 ubiquitination and 
acetylation are mutually exclusive events where acetylation of the p53 C 
terminus (which includes K379) prevents its ubiquitination of by MDM2 
(Rodriguez et al., 2000; Sakaguchi et al., 1998; Ito et al., 2001; Li et al., 2002). 
We therefore proposed that an interesting concept where Stra13 mediated 
acetylation of p53 K379 could have prevented the subsequent ubiquitination 
attempt by MDM2, thus preventing the degradation of p53. However, with the 
introduction of Sirt1, p53 K379 is deactylated to allow for MDM2 mediated 
ubiquitination to occur, leading to p53 destabalization.   
4.5. A p53 independent role of Stra13 in senescence 
Despite having established the dependency of Stra13 on p53 in mediating 
senescence, Stra13 seems to also have a p53 independent role in inducing 
senescence. This is evident in the inability of p53 deficiency to fully rescue the 
senescence phenotype induced by Stra13 overexpression (Figure 3.2 C). A 
similar trend is observed the MCF7 model utilized by Qian et al., 2008. 
A highly plausible explanation for the above phenomenon would lie in the 
transcriptional repressive functions of Cyclin D1 by Stra13. Our laboratory 
has previously reported that Stra13 overexpression is associated with growth 
arrest and this is accompanied by a delayed progression in the G1/S phase of 
the cell cycle, leading to G1 arrest (Sun and Taneja, 2000; Wang et al., 2012). 
In addition, Stra13 has been shown by two separate groups to inhibit Cyclin 
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D1 to impact cell proliferation. This occurs via the transcriptional repression 
of Cyclin D1 (Bhawal et al., 2011; Liu et al., 2013). Taken together, the G1 
arrest occurring in Stra13 overexpressed cells is a direct effect of the 
repression of CyclinD1 which is an important Cyclin governing the G1/S 
phase transition of cell cycle. 
In the absence of p53 as the main driver for senescence, Stra13 may still have 
a transcriptional repressive effect on Cyclin D1. This allows Stra13 to 
circumvent the p53 pathway of inhibiting inducing cell arrest and directly 
target the cell cycle itself and ultimately leading to the onset of senescence.  
Stra13 role in inducing a G1 arrest seems to be reminiscent to targeting the 
p16INK4A- Retinoblastoma pathway in a p53 deficient environment where 
p16 is able to inhibit cyclin dependent kinases (CDKs) 4, 6 which complex 
with Cyclin D1 to regulate the G1/S phase transition, resulting in senescence 
(Kaelin, 1999). However, instead of targeting the CDKs, Stra13 affected 
Cyclin D1 to result in the same phenotypic effect as p16INK4A activation. 
4.6. Sirt1 effect on Stra13 
The discovery of Sirt1 as a novel deacetylation target of Sirt1 has brought the 
Stra13-p53-Sirt1 mechanistic relationship demonstrated in the thesis to a new 
level of complexity, prompting the question of whether alteration of Stra13 
acetylation status affects its p53 dependent and/ or p53 independent activities.  
However to date, the only known post translational modification of Stra13 is 
sumoylation of its lysine residues at positions 159 and 279 located in the C 
terminal region. Mutation of these two sumoylation sites abrogates Stra13 
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mediated repression of both Cyclin D1 transcription and G1/S phase cell cycle 
progression. In addition, HDAC1 deacetylase overexpression abolishes Stra13 
sumoylation and confer cellular phenotypes identical to cells expressing 
sumoylation defective Stra13 (Wang et al., 2012). This suggests an 
acetylation-dependent sumoylation mechanism seen in PML post translational 
modification at play given that HDAC1 do not have intrinsic desumoylation 
activity (Hayakawa et al., 2008). 
It would therefore be interesting to investigate if Sirt1 deacetylation of Stra13 
would have a similar effect as HDAC1 on Stra13 sumoylation. This would 
hint to a similar regulatory role of Sirt1 and HDAC1 in regulating Stra13 
sumoylation status and possibly Cyclin D1 transcription. 
In addition, deacetylation of Stra13 by Sirt1 could also be hypothesized to 
affect the Stra13 mediated p53 acetylation and expression which is 
demonstrated in this thesis. As Sirt1 overexpression does not affect 
endogenous Stra13 mRNA levels, the effect of Stra13 deacetylation by Sirt1 
would have been targeted at activity of Stra13 (Figure 3.5). This proposed 
alteration in Stra13 activity could have encompass its transcriptional activity 
on its target genes such as Cyclin D1 and/or the hypothesized ability to recruit 
acetyl transferase p300 to catalyze acetylation of p53 lysine 379 (discussed in 
section 4.3). Sirt1 mediated decrease of Stra13 acetylation may be 
hypothesized to disrupt its proposed binding to p300 and thus ultimately 





4.7. NIH3T3 as a model of senescence 
The use of NIH3T3 in the study of senescence is not new. Various studies 
have utilized it as a model for understanding the dynamics of chemical and 
stress induced senescence (Xiao et al., 1997 and Chatterjee et al., 2011). In 
addition, the ease of transfecting NIH3T3 has made it a popular choice for 
overexpression of proteins of interest in senescence studies (Hsu et al., 2012; 
Li et al., 2008; Yuan et al., 2008; Zhao et al., 2006).  
Being an immortalised mouse embryonic cell line, NIH3T3 has bypass the 
onset of replicative senescence to achieve immortality. Therefore majority of 
senescence studies utilizing the NIH3T3 model revolves around the analysis of 
premature senescence rather than replicative (Hsu et al., 2012; Chatterjee et al., 
2011; Rizzo et al., 2011). This is advantageous for our study as it would 
ensure that the senescence phenotypes arises from direct effect of Stra13 and 
is not confounded by onset of senescence due to limited doubling potential of 
cells. 
It should also be noted that NIH3T3 bears deletion in the INK4a locus which 
encodes for both p16INK4A and p19ARF proteins that are upstream 
regulators of retinoblastoma and p53 respectively (Calabrò et al., 1999 and 
Linardopoulos et al., 1995). Loss of INK4a locus is postulated be necessary to 
bypass replicative senescence and achieve immortality. Mechanistic studies of 
the p53 or retinoblastoma mediated senescence pathways in NIH3T3 would 
therefore need to exclude p16INK4A and p19ARF proteins in the study.  In 
the case of our studies of the Stra13-p53- Sirt1 pathway of regulating 
senescence, deficiency of p19ARF would translate into decreased inhibition of 
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the MDM2 activity. Increased MDM2 activity may have dampen p53 levels 
















5. Conclusion and future studies 
This research study essentially establishes Stra13 as a mediator of senescence 
in NIH3T3 cells via a p53 dependent manner. This is achieved via acetylation 
of p53 K379 leading to increased p53 stability and the onset of premature 
senescence. In addition, this study shows that Sirt1, a NAD
+
 dependent histone 
deacetylase functions as an antagonist of the Stra13-p53 pathway by 
deactylating p53 K379. Deacetylation at p53 K379 destabilizes p53 protein 
and rescues senescence imposed by Stra13. Thus this study presents a novel 
mechanism that regulates p53 acetylation via antagonistic effects of Stra13 
and Sirt1.  
A critical piece of puzzle still missing in this study is the mechanism by which 
Stra13 induces p53 acetylation. There are no reports about Stra13 possessing 
the intrinsic acetyltransferase function. Our studies suggest that Stra13 may 
recruit of p300/CBP to acetylate p53 K379 (discussed in Section 4.3).  
To investigate the above hypothesis, the physical interaction of Stra13 and 
CBP/p300 would have to be established by immunoprecipitation assays. 
Furthermore, analysis of p53 K379 acetylation in a CBP/p300 knockdown 
environment where Stra13 is also overexpressed would also determined if 
Stra13 mediated p53 acetylation is a CBP/p300 dependent process. 
The inability of p53 knockdown to fully rescue Stra13 mediated senescence 
suggests that Stra13 also induces senescence via p53 independent mechanisms. 
One possible mechanism in this regard could be via transcriptional repression 
of Cyclin D1 by Stra13 (Bhawal et al., 2011; Liu et al., 2013) (discussed in 
section 4.5).  
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Proving the above hypothesis requires the analysis of Cyclin D1 protein level 
and Stra13 mediated Cyclin D1 promoter activity in a NIH3T3 setup 
overexpressing Stra13 in a p53 knockdown context to establish Cyclin D1 
involvement in Stra13’s p53 independent induction of senescence. Ectopic 
Cyclin D1 expression in an attempt to rescue Stra13’s p53 independent 
induction of senescence would then complement and validate the above 
experiments. 
Finally, the discovery of deacetylation of Stra13 by Sirt1 adds to the limited 
but growing repertoire of Stra13 post translational modifications (Wang et al., 
2012). For instance, recent studies from our lab have shown that Stra13 is 
sumoylated (Wang et al., 2012). Sirt1 mediated Stra13 deacetylation may alter 
its subsequent sumoylation to result in alteration of Stra13 transcriptional 
acivity on Cyclin D1 gene (discussed in section 4.6). 
The identification of the specific lysine sites on Stra13 which are deacetylated 
by Sirt1 would be essential prior to studying if these sites are also sumoylation 
target residues. After the establishment of potential lysine residues on Stra13 
that can be deacetylated by Sirt1 or sumoylated, the analysis of the inhibition 
of sumoylation at these residues by the Sirt1 deacetylase activity could then be 
carried out. Site directed mutation of these residues to non-sumoylated amino 
acids would then be applied to study the ability of these mutants in mediating 
transcriptional regulation of Stra13 target genes such as Cyclin D1. 
In summary, we have provided novel insights into the regulation of p53 
mediated senescence and acetylation via the antagonism of Stra13 and Sirt1. 
Together, current research findings and proposals of future research directions 
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would position this study as an invaluable tool in understanding the mechanics 














Table I. Smart pool siRNA Sequences for Non-Targeting siRNA 
Target Name Sequence (5’-3’ forward) Supplier 







Non targeting siRNA-2 UGGUUUACAUGUUGUGUGA  
 
Non targeting siRNA-3 UGGUUUACAUGUUUUCUGA  
 




Table II. Smart pool siRNA Sequences for siSirt1 








siSirt1-2 GCGGAUAGGUCCAUAUACU  
 
siSirt1-3 CCGAUGGACUCCUCACUAA  
 




Table III. Smart pool siRNA Sequences for siTrp53 








siTrp53-2 AAAUUUGUAUCCCGAGUAU  
 
siTrp53-3 GAGGAGUCACAGUCGGAUA  
 









Table IV. Smart pool siRNA Sequences for siStra13 


















Table V. Primers for real time PCR (Q-PCR) 
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